SlideShare a Scribd company logo
1 of 113
Therapeutic Goods
Advertising Code (No. 2) 2018
The Code basics
Leanne McCauley & Alexandra Dance
Advertising Education and Assurance Section
Regulatory Education and Compliance Branch
Regulatory Practice and Support Division
Health Products Regulation Group
20 November 2018
Website and link references
• Details of the TGA’s advertising complaints handling framework has been published:
https://www.tga.gov.au/publication/complaints-handling-advertising-therapeutic-goods-australian-public
• TGA statement on its approach to compliance and enforcement discretion in the changeover to 2018
Code: https://www.tga.gov.au/therapeutic-goods-advertising-update-29-october-2018
• Advertising hub – www.tga.gov.au/advertising-hub
– Online training module – more to come
– Australian Regulatory Guidelines for Advertising Therapeutic Goods
• Regulatory affairs consultant / legal advice
• TGA Online advertising inquiry form - https://compliance.tga.gov.au/advertising-enquiry/
1
Role of the Advertising Code
• The Code is the cornerstone of the advertising framework
–Requires that advertising supports appropriate use of
therapeutic goods and does not mislead or deceive
• Current version is 2015 Code – until 31 December 2018
• The Code was revised to provide clarity and more
objective tests to support sanctions and penalties
2
Compliance with Advertising Code
• Advertising to the public for therapeutic goods MUST
comply with the Advertising Code
• Requirement to comply with the Code is specified through
a criminal offence and civil penalty provision in the Act:
–Section 42DM – criminal offence
–Section 42DMA – civil penalty
• For an ad to be approved under the Regulations, the
delegate must be satisfied that it complies with the Code
3
About the 2018 Code
• The 2018 Code was made on 31 October 2018, to take
effect on 1 January 2019
• Principles underpinning 2015 and 2018 Codes are similar
• The 2018 Code is supported by specific guidance
4
Code version for pre-approvals
• Ads for medicines to appear in specified media require pre-
approval under Regulation 5G
• For pre-approval decisions made:
–On or after 1 January 2019: 2018 Code applied
–On or before 31 December 2018: 2015 Code applied
• You must allow time for the process, any revisions and
Christmas shut downs
5
Code version applied in compliance
• For ads with current approval: version of Code approved
under
• For ads (other than pre-approved ads) that occurred:
Advertising occurred Assessed against
On or after 1 January 2019 2018 Code
Before 1 January 2019 and is no longer
occurring
2015 Code
Before 1 January 2019 and is still occurring 2018 Code
6
Compliance approach
• Details of the TGA’s advertising complaints handling
framework has been published:
https://www.tga.gov.au/publication/complaints-handling-
advertising-therapeutic-goods-australian-public
• TGA statement on its approach to compliance and
enforcement discretion in the changeover to 2018 Code:
https://www.tga.gov.au/therapeutic-goods-advertising-
update-29-october-2018
7
Scheduling of medicines
• No advertising to consumers
• S3 – only Appendix H can be
advertised
• Can be advertised to
consumers
• S8 - Drugs of Dependence – by prescription
• S4 - By prescription only
• S3 - Pharmacist only – behind the counter
• S2 - Pharmacy only
• Unscheduled – General sales item
8
The Therapeutic Goods
Advertising Code 2018
in detail
9
Structure of the 2018 Code
• Part 1 – Preliminary – definitions, object, application
• Part 2 – General requirements for advertising therapeutic goods
• Part 3 – Specific rules relating to particular therapeutic goods
• Part 4 – Prohibited & restricted representations
• Schedule 1 – Medicines with specific health warnings
• Schedule 2 – Advertising to children
• Schedule 3 – Samples
• Schedule 4 – Price information
• Schedule 5 – Repeals 10
Part 1 - Preliminary
11
Section 4 - Definitions
• It is important to read the Code in conjunction with the Act
and the Therapeutic Goods Regulations 1990
–Terms that are not defined in the Code may be defined in
the Act and Regulations (e.g. ‘advertise’)
• Most Code definitions straightforward but there are some
that we will explore in detail:
–Health warning
–Prominently displayed or communicated
12
What are health warnings?
• In some cases, health warnings need to be included in ads
• Concept of ‘health warning’ is defined in s.4 of the Code
• The purpose of health warnings is to alert consumers to
information that will be critical to the consumer's
assessment of whether the advertised product is right for
them before purchase
13
Health warning definition - medicines
• Health warnings for medicines are prescribed in Schedule 1 of
the Code
• Schedule 1 health warnings are:
– an exhaustive list but may be updated from time to time
– based on RASML, permitted ingredients determination, TGO69
and TGO92
– divided into different parts for warnings for registered
medicines, listed medicines and both types of medicines
14
Example of medicine health warnings
1. Ingredients 2. Circumstances 3. Health warning
Hydroxyanthracene derivatives such as those from:
• Aloe
• Buckthorn
• Cascara
• Frangula
• Rhubarb
• Senna
In preparations for oral use where the MRDD contains
MORE than 10mg
Do not use if you have abdominal pain, nausea, vomiting
or diarrhoea
Ibuprofen/Paracetamol combinations In preparations for oral use Do not use if you have a stomach ulcer, impaired kidney
function, heart failure, allergic to anti inflammatory
medicines, pregnant or trying to become pregnant
15
Health warning definition – devices/OTGs
…a statement that is required under the Act or Regulations or Medical Devices Regulations to
be included on the label or in instructions for use that warns that a person who takes or uses the
device or goods as intended may:
(i) die; or
(ii) require hospitalisation or a longer period of hospitalisation than would be required if the
person had not taken or used the device or goods; or
(iii) require a medical practitioner to treat or prevent injury, disability, incapacity or impairment of
any bodily function, organ or structure as a consequence of taking or using the device or goods
16
Prominently displayed or communicated
‘prominently displayed or communicated’ is defined as:
(a) either:
(i) for a visual statement-standing out so as to be easily read from a reasonable viewing
distance for the particular media type in the context in which the advertisement is intended
to be viewed; or
(ii) for a spoken statement-able to be clearly heard and understood; and
(b) repeated as often as is necessary to ensure that it is likely to be noticeable for a
viewer or listener.
17
Section 5 – Object of the Code
“...to ensure that the advertising of therapeutic goods to
consumers is conducted in a manner that:
(a) promotes the safe and proper use of therapeutic goods by
minimising their misuse, overuse or underuse; and
(b) is ethical and does not mislead or deceive the consumer or
create unrealistic expectations about product performance; and
(c) supports informed health care choices; and
(d) is not inconsistent with current public health campaigns.“
18
Section 6 – Application
• Applies to:
– The advertising of therapeutic goods (ss.6(1))
– By any person advertising or causing advertising (ss.6(5))
• Does not apply to:
– Genuine news (ss.6(6)) by certain bodies (ss.6(7)) – including broadcasters, datacasters
and publishers
– Advertising directed exclusively to health professionals (ss.6(2))
19
Section 6 – Application
• How to apply the Code to a particular advertisement:
– consider its likely impact on a reasonable person to whom the advertisement is directed
(ss.6(3))
– the total presentation and context of the advertisement is to be taken into account
(ss.6(4))
20
Audience advertisement directed to
• Advertising may be directed to the public in general or a sub-population
• A direction may be made in many forms, including:
– An overt statement e.g. “Do you suffer from cold sores?”, “For the relief of
psoriasis”
– An implied call to capture the attention of a sub-population e.g. for the
measurement of blood pressure
– The location of the ad e.g. in a magazine for diabetics
21
Total presentation & context
• Total presentation: the advertisement as a whole
• Context includes:
– What other information is provided around the advertisement that could
change the take-out message? e.g. an editorial on a page opposite the
advertisement
– Does the environment in which it is displayed have the potential to alter the
take-out message? E.g. a billboard ad that is viewed when passing in a car
at speed
22
Example – reasonable consumer
23
Example – Bean’s Tonic
24
Section 6A & 6B – Repeals & transition
• Section 6A, by reference to Schedule 5, repeals the 2015
Code and the original 2018 Code
• Section 6B allows for a transition period for ads pre-
approved under the 2015 Code – i.e.
–Complaints about such ads will be assessed against the
2015 Code for the life of the approval
25
Section 7 - Price information
• Price information – definition in s.4 of Code – relates to prescription medicines
and pharmacist-only medicines only
• S.42DL(10) of the Act – advertising of prescription medicines to the public
prohibited “other than a reference authorised or required by a government or
government authority”
• Section 7 of the Code authorises the dissemination of price lists that comply
with Schedule 4 of the Code – i.e. not an offence under the Act
• Schedule 4 replaces Price information code of practice
26
Part 2 - Requirements for advertising all
therapeutic goods to the public
27
Section 8 – Approved ads
• Ads for medicines for ‘specified media’ (e.g. free-to-air
television, newspaper, billboard) require prior approval
under Regulation 5G
Arises from offence under section 42C of Act
• S.8 requires ads appearing in print media and billboards to
display the approval number in the advertisement as set
out in ss.8(3) – must be legible
28
S.9 – Accuracy: validity & substantiation
Advertising for therapeutic goods must satisfy the following:
(a) any claims made in the advertising are valid and accurate,
and all information presented has been substantiated before the
advertising occurs
Example: An ad promotes a medical device for identifying allergies
from a non-invasive sample from the patient. The advertiser states
the claim is supported by a small clinical trial conducted in the
1960s. Subsequent larger studies failed to reproduce the positive
findings. The claims are not valid.
29
S.9 – Accuracy: truthful & not misleading
Advertising for therapeutic goods must satisfy the following:
(b) it is truthful, balanced and not misleading or likely to mislead, including in
its claims, presentations, representations and comparisons
Example: an imaging device is advertised as producing 5 times less radiation
than other devices but fails advise that the amount of radiation produced by
such devices is very small. It is likely to mislead consumers:
• into thinking other imaging devices are harmful
• as to the order of magnitude of the difference in radiation produced by the
devices – even if the claim is substantiated.
30
S.9 – Accuracy: comparisons
Advertising for therapeutic goods must satisfy the following:
(c) any comparisons made in the advertising between
therapeutic goods or classes of therapeutic goods do not directly
or indirectly claim that the goods or class of goods being used as
the comparator are harmful or ineffectual;
Example: A head lice product is promoted as being more effective
and safer than the leading brand, which has an ingredient shown to
cause birth defects
31
S.9 – Accuracy: consistency with ARTG
Advertising for therapeutic goods must satisfy the following:
(d) if the goods are included in the Register - it is consistent with
the entry for the therapeutic goods in relation to that
inclusion.
Example: A product is included in the ARTG for the relief of pain in
adults aged 18-65 only. If the product was promoted for pain relief
for children, it would contravene s.9(d).
32
S.10 – Effect: support proper use
(a) Advertising for therapeutic goods must support the safe and
proper use of therapeutic goods by:
(i) presenting the goods in accordance with directions or
instructions for use; and
(ii) not exaggerating product efficacy or performance;
Example: A topical preparation for the relief of symptoms of eczema
is promoted for oral consumption as it works faster
33
S.10 – Effect: delaying appropriate treatment
(b) Advertising for therapeutic goods must…not be likely to lead to
people delaying necessary medical attention or delaying the use of,
or failing to use, treatment prescribed by a medical practitioner;
Example: a herbal medicine is promoted as an alternative to
antibiotics and people should use it as first line treatment for
conjunctivitis and other infections instead of antibiotics
34
S.10 – Effect: encourage inappropriate use
(c) Advertising for therapeutic goods must not encourage
inappropriate or excessive use of the therapeutic goods
Example: A medical device for alleviating snoring is promoted for
alleviating sleep apnoea. The advertising would be likely to
encourage inappropriate use.
35
S.10 – Effect: safe or cannot harm
(d) Advertising for therapeutic goods must not contain any claim,
statement, implication or representation that:
(i) the therapeutic goods are safe or that their use cannot cause
harm, or that they have no side-effects
Example: A herbal medicine is promoted as having a safe mode of
action and that millions of people have bought it and there have
been no adverse reports.
36
S.10 – Effect: sure cure
(d) Advertising for therapeutic goods must not contain any claim,
statement, implication or representation that…
(ii) the therapeutic goods are effective in all cases of a condition
or that the outcome from their use is a guaranteed or sure cure;
Example: A medical device is promoted as guaranteed to improve
lung function by 75% in COPD patients
37
S.10 – Effect: miraculous
(d) Advertising for therapeutic goods must not contain any claim,
statement, implication or representation that…
(iii) the therapeutic goods are infallible, unfailing, magical or
miraculous;
Example: A testimonial on a website for a medicine for relieving
cystitis states the product is miraculous and the symptoms were
gone within two hours and did not return.
38
S.10 – Effect: harmful consequences
(d) Advertising for therapeutic goods must not contain any claim,
statement, implication or representation that…
(iv) harmful consequences may result from the therapeutic
goods not being used - unless the claim, statement, implication or
representation is permitted under section 42DK of the Act or
approved under section 42DF of the Act.
Example: An ad for a supplement for 65+ year olds is promoted by
stating that retirees won’t be able to continue playing golf and
keeping up with their grandkids unless they use the supplement
39
Sections 11 - 13
Mandatory information and
statements
40
Overview: application of sections
Section 11 Section 12 Section 13
Ad for S3 (App H) medicine

Ad for non-S3 therapeutic good
that allows purchase without
seeing the good
 
(selected
items only)
Any other ad for non-S3
therapeutic good

Note: other provisions in the Code, including Part 3, will still apply in each case 41
S.11: Required statement – S3s
• An advertisement for a medicine containing a substance included in Schedule
3 of the Poisons Standard and Appendix H must prominently display or
communicate:
ASK YOUR PHARMACIST -THEY MUST DECIDE IF THIS PRODUCT IS
RIGHT FOR YOU
• This is the only mandatory statement required by Part 2 for S3 medicines
advertising
– Part 3 still applies – e.g. analgesics warning
• Does not apply to labels, CMIs or PILs
42
Section 12 & 13 requirements
Ad must prominently display or communicate:
• Basic info about the goods
• Important health information (or a prompt to consumers to read it)
• Advice to follow directions
• A symptom statement (if there are claims about symptoms
43
S.12: What must ads contain (goods not
available for inspection)
• This section is only for ads for goods that are not available for
physical examination by the consumer before or at the time of
purchase (e.g. internet, mail order marketing)
• Does not apply to:
– advertisements subject to section 11
– a label, consumer medicine information or a patient information
leaflet
44
Section 12 mandatories: medicines
Type of information Provision and the information required in ad
Basic information about
the goods
• ss.12(3)(a) – (c) – the name of the medicine, dosage form, the quantity of
the medicine
• ss.12(3)(d) - one or more of the indications for the medicine, as they appear
on the medicine’s label
• ss.12(3)(e) - a list of certain ingredients – see definition in s.4
Important health
information
• ss.12(3)(f) – an alert to the consumer to read the label or warnings (as
appropriate for the nature of the medicine)
Follow the directions
statement
• ss.12(3)(g) – ‘Follow the directions for use’ or ‘Follow the instructions for
use’ from ss.13(6)
Symptom statement • ss.12(3)(h) - If there are symptoms claims in ad, include appropriate
statement/s from ss.13(7)
45
ss.12(3)(f): Important health info for medicines
Are there health warnings in
Schedule 1 of the Code for the
medicine?
Do you want to include the health warnings in the
ad?
USE: ‘This medicine may not be right for you. Read the
warnings before purchase’
followed immediately by information about where the
health warnings can be found
USE: ‘Always read the label’ and
the health warnings
USE: ‘Always read the label’
NoYes
No Yes
46
Section 12 mandatories: devices
Type of information Provision and the information required in ad
Basic information
about the goods
• ss.12(4)(a) – (b) – an accurate description and a reference to
EITHER the trade name or another name for the device
• ss.12(4)(c) – the intended purpose or indications for the device
as they appear on label or primary packaging
• ss.12(4)(d) - a list of the ingredients if applicable
Important health
information
• ss.12(4)(e) – an alert to the consumer to read the label,
instructions or warnings (as appropriate for the device)
Follow the directions
statement
• ss.12(4)(f) – ‘Follow the directions for use’ or ‘Follow the
instructions for use’ from ss.13(6) as appropriate for the device
Symptom statement • ss.12(4)(g) - If there are symptoms claims in ad, include
appropriate statement/s from ss.13(7) 47
ss.12(4)(e): Important info for devices
Are there statements on the label or instructions for use for the
device that meet the definition of ‘health warning’ in section 4 of
the Code?
Do you want to include the health warnings in the
ad?
USE: ‘This product may not be right for you. Read the
warnings before purchase’
followed immediately by information about where the
health warnings can be found
USE: ‘Always read the
label/instructions for use’ and the
health warnings
USE: ‘Always read the
label/instructions for use’
NoYes
No Yes
48
Section 12 mandatories: OTGs
Type of information Provision and the information required in ad
Basic information
about the goods
• ss.12(5)(a) – (b) – an accurate description and a reference to
EITHER the trade name or another name for the goods
• ss.12(5)(c) – the intended purpose or indications for the goods
as they appear on label or primary packaging
• ss.12(5)(d) - a list of the ingredients where relevant
Important health
information
• ss.12(5)(e) – an alert to the consumer to read the label,
instructions or warnings (as appropriate for the goods)
Follow the directions
statement
• ss.12(5)(f) – ‘Follow the directions for use’ or ‘Follow the
instructions for use’ from ss.13(6) as appropriate for the goods
Symptom statement • ss.12(5)(g) - If there are symptoms claims in ad, include
appropriate statement/s from ss.13(7) 49
ss.12(5)(e): Important info for OTGs
Are there statements on the label or instructions for use for the
goods that meet the definition of ‘health warning’ in section 4 of the
Code?
Do you want to include the health warnings in the
ad?
USE: ‘This product may not be right for you. Read the
warnings before purchase’
followed immediately by information about where the
health warnings can be found
USE: ‘Always read the
label/instructions for use’ and the
health warnings
USE: ‘Always read the
label/instructions for use’
NoYes
No Yes
50
Examples: Bean’s Tonic
internet marketing
51
Example – Bean’s Tonic internet
marketing
52
S.13: What must ads contain (general)
• This section is only for ads that:
– are for goods other than Schedule 3 medicines (see s.13(1)(d) - section 11
applies to these)
– do not facilitate purchase of the goods without the consumer being able to
inspect them (see s.13(1)(e) - section 12 applies to these)
• This section does not apply to labels, consumer medicine information or a
patient information leaflet (s.13(1)(a) & (b))
53
S.13: What must ads contain (general)
• This section also does not apply to picture/price/point of
sale ads (see s.13(1)(c)) – i.e.:
–an advertisement displaying only the name or picture of
therapeutic goods or their price or point of sale, or any
combination of these, provided the advertisement does
not contain or imply a claim relating to therapeutic use,
or any other representation
54
Section 13 mandatories: medicines
Type of information Provision and the information required in ad
Basic information
about the goods
• ss.13(2)(a) – (b) – a reference to the trade name of the
medicine and one or more of the indications as they appear on
label
Important health
information
• ss.13(2)(c) – an alert to the consumer to read the label,
instructions or warnings (as appropriate for the goods)
Follow the directions
statement
• ss.13(6) – ‘Follow the directions for use’ or ‘Follow the
instructions for use’ as appropriate for the goods
Symptom statement • ss.13(7) - If there are symptoms claims in ad, include
appropriate statement/s
55
ss.13(2)(c): Important info for medicines
Are there health warnings in Schedule 1 of the Code for the
medicine?
Do you want to include the health warnings in the
ad?
USE: ‘This medicine may not be right for you. Read the label
before purchase’
USE: ‘Always read the label’ and
the health warnings
USE: ‘Always read the label’
NoYes
No Yes
56
Section 13 mandatories: devices
Type of information Provision and the information required in ad
Basic information
about the goods
• ss.13(3)(a) – (b) – an accurate description and a reference to
EITHER the trade name or another name for the device
• ss.13(3)(c) – the intended purpose or indications for the device
Important health
information
• ss.13(3)(d) – an alert to the consumer to read the label,
instructions or warnings (as appropriate for the device)
Follow the directions
statement
• ss.13(6) – ‘Follow the directions for use’ or ‘Follow the
instructions for use’ as appropriate for the device
Symptom statement • ss.13(7) - If there are symptoms claims in ad, include
appropriate statement/s
57
ss.13(3)(d): Important info for devices
Are there statements on the label or instructions for use for the device
that meet the definition of ‘health warning’ in section 4?
Do you want to include the health warnings in the ad?
USE: ‘This product may not be right for you. Read the label/instructions for
use before purchase’
depending on whether there is a label visible on primary pack
USE: ‘Always read the
label/instructions for use’ and the
health warnings
USE: ‘Always read the label/instructions for
use’
NoYes
No Yes
58
Section 13 mandatories: OTGs
Type of information Provision and the information required in ad
Basic information
about the goods
• ss.13(4)(a) – (b) – an accurate description and a reference to
EITHER the trade name or another name for the goods
• ss.13(4)(c) – the intended purpose or indications for the goods
Important health
information
• ss.13(4)(d) – an alert to the consumer to read the label or
instructions (as appropriate for the goods)
Follow the directions
statement
• ss.13(6) – ‘Follow the directions for use’ or ‘Follow the
instructions for use’ as appropriate for the goods
Symptom statement • ss.13(7) - If there are symptoms claims in ad, include
appropriate statement/s
59
ss.13(4)(d): Important info for OTGs
Are there statements on the label or instructions for use for the goods
that meet the definition of ‘health warning’ in section 4?
Do you want to include the health warnings in the ad?
USE: ‘This product may not be right for you. Read the label/instructions
for use before purchase’
depending on whether there is a label visible on primary pack
USE: ‘Always read the
label/instructions for use’ and the
health warnings
USE: ‘Always read the label/instructions
for use’
NoYes
No Yes
60
Exemptions from parts of section 13:
short form ads
• “Short form ads” are:
–Radio commercials 15 seconds or less duration
–Text-only ads of 300 characters or less with no ability to
include pictures, logos or other imagery
• Short form ads are exempt from:
–The calls to action – ‘Always read the label’ etc
–Symptoms statement (ss.13(6)) 61
Examples: Bean’s Tonic
magazine ads
62
Example 1 –
Bean’s Tonic
An example of
prominently displayed
mandatories for a
medicine without
health warnings
63
Example 2 –
Bean’s Tonic
An example of prominently
displayed mandatories for a
medicine with health warnings -
using mandatories option 1 and 2
64
Example 4 –
Bean’s Tonic
Will not be compliant
under the Code
65
S.15: Scientific or clinical representations
• Ss.15(1) - this section does not apply to labels, CMIs or
PILs
• This section is in two parts:
–Requirements for use of scientific or clinical claims
(ss.15(2))
–Requirements for use of citations (ss.15(3))
66
S.15(2): Scientific or clinical claims
Where an advertisement makes a scientific or clinical claim:
• (a) any scientific or clinical terminology must be
appropriate, clearly communicated and able to be readily
understood by the audience to whom it is directed; and
• (b) any scientific or clinical representation must be
consistent with the body of scientific or clinical evidence
applicable to the advertised therapeutic goods.
67
S.15(3): Scientific citations
Where an advertisement contains a citation to scientific or
clinical literature, either explicitly or impliedly:
• (a) any research results must identify the researcher and
financial sponsor of the research, where the advertiser
knows, or ought reasonably to have known that
information; and
• (b) the study must be sufficiently identified to enable
consumers to access it. 68
Example Implied scientific
citation – reference
needs to be
provided
Scientific
information is
inappropriate and
won’t be readily
understood
These would need
to reflect the body
of evidence
available
69
Example
Provided these
claims reflect the
body of evidence
available about the
product or
ingredient, this
would likely
comply with s.15
70
S.16(1): Endorsements
• The endorsement provisions in section 16 do not apply to:
–Testimonials captured by section 17 (s.16(1)(a))
–Claimer for efficacy assessed non-prescription medicines
– as described in Regulations (s.16(1)(b))
71
S.16(2) and (2A): Endorsements
• Endorsements (express or implied) from the following are prohibited:
(a) a government authority, hospital or healthcare facility; or
(b) an employee or contractor of a government agency, hospital or
healthcare facility; or
(c) a health practitioner, health professional, medical researcher or
a group of such persons.
• Health care facilities do not include community pharmacies
72
S.16(3): Endorsements
Subject to conditions, endorsements from the following are permitted:
(a) an organisation that:
(i) represents the interests of healthcare consumers; or
(ii) represents the interests of health practitioners, health
professionals or medical researchers; or
(iii) conducts or funds research into any disease, condition, ailment
or defect; or
(b) an employee or contractor of an organisation mentioned above,
other than an individual mentioned in paragraph (2)(b) or (c) 73
S.16: Endorsement conditions
• Endorsements made under s.16(3) are subject to the conditions
that the advertisement:
– names the organisation concerned; and
– discloses:
(i) the nature of the endorsement; and
(ii) whether the organisation or employee, has received, or will
receive, any valuable consideration for the endorsement
• ‘Organisation’ defined in s.16(4) – any group, association etc
74
S.17: Testimonials
• Testimonial = a statement about a therapeutic good made by a
person that claims to have used that good (s.17(1))
• This section specifies three types of requirements:
– Characteristics of the person making testimonial (s.17(2)(a))
– Obligations of the advertiser before using testimonial in
advertising (s.17(2)(b) and (c))
– Information that must be disclosed in the ad about the
testimonial (s.17(3))
75
Who can make a testimonial for use in ads?
s.17(2)(a) - a person:
(i) whose details are verified prior to the advertising occurring; and
(ii) who has used the goods for their intended purpose; and
(iii) who is not:
(A) involved with the production, sale, supply or marketing of the goods; or
(B) an employee or officer of a corporation that is involved with the
production, sale, supply or marketing of the goods; or
(C) a corporation; or
(D) mentioned in subsection 16(2) (e.g. health professionals, staff from
government agency, hospital or healthcare facility)
76
Advertiser obligations when using testimonials
s.17(2)(b) and (c) – the advertiser needs to ensure that they
have:
• verified as to the use of the goods and the claims made by
the person prior to the advertising occurring; and
• checked that the testimonial is typical of the results to be
expected from the use of the goods in accordance with the
directions for use, or purpose, of the goods.
77
Information re testimonials to be included in ads
s.17(3) – An ad containing a testimonial must:
(a) disclose whether the person providing the testimonial has
received, or will receive, any valuable consideration for the
testimonial;
(b) disclose where another person is taking the place in the
advertisement of the person providing the testimonial; and
(c) disclose where the person providing the testimonial is an
immediate family member of an individual who is involved with
the production, sale, supply or marketing of the goods.
78
Example acceptable use policy
• We welcome your comments on our page but we ask that you help us comply with the Therapeutic Goods Advertising Code (the
Code).Please consider these guidelines before commenting. We will remove any comments that may result in us breaching the
Code.
• We love when you comment and tag your friends and family on our posts but we ask that you do not:
• endorse our product if you are:
– an employee or contractor of a government authority, a hospital or a healthcare facility
– a health practitioner, health professional or medical researcher
– involved with the production, sale, supply or marketing of our product
– not using your own name on this social media platform.
• imply that a government authority, a hospital or a healthcare facility endorse our product
• make comments about how a product works for you outside of its intended purpose, as these comments can be dangerous or
misleading.—our products are developed for particular purposes, as stated on the label and/or in our advertising, and these
comments can be dangerous and misleading
– make comments about serious conditions, diseases, ailments or defects, such as comments about how a product helped with
your cancer treatment or how it will relieve a tagged person’s rheumatoid arthritis pain
• We also have an obligation to make sure any advertisements we make, including endorsements and testimonials, are not
misleading. Therefore we promise to disclose:
• where a person has been, or will be, compensated for making a testimonial
• where we have actors making the testimonial, such as in cases where the original person who made the testimonial does not want
to appear in our advertisement
• where the person making the testimonial is an immediate family member of anyone employed by our business
79
S.18: Incentives
• Ads must not offer any personal incentive to a pharmacy assistant,
or any retail sales person who is not a health professional, to
recommend or supply therapeutic goods.
• Pharmacy assistants and other retail staff do not meet the criteria
for ‘health professionals’ for the purposes of the advertising
(s.42AA)
• Ads for these audiences must comply with the Code – including
this provision
80
S.19: Advertising to children
• Advertising must not be primarily directed to children
under the age of 12 years at all
• Advertising must not be primarily directed to children aged
12 years or over, EXCEPT for those products listed in
Schedule 2 of the Code, which include tampons and condoms
• Labels are excluded from this provision
• ‘primarily directed’ does not include incidental exposure
81
S.20: Samples
• An ad must not contain an offer of a sample EXCEPT for those products listed
in Schedule 3:
condoms
Sunscreens
Stoma devices for self-management
Continence catheter devices for self-management
• Samples can in themselves be an ad – consider Act definition of ‘advertise’
• Some samples may also be subject to state and territory laws – e.g.
scheduled substances
82
S.20: Samples example
NOT COMPLIANT
Have you been diagnosed with IBS recently?
Wondering if you will ever find anything to help your symptoms?
You can feel better in just two weeks – take the Bean’s challenge!
Sign up at www.beanstonic.com.au and we will email you a voucher for a free one
month supply of Bean’s Tonic from your local pharmacy
83
S.21: Consistency with public health campaigns
• If a relevant public health campaign of which the advertiser
knows, or ought reasonably to have known is or will be current
at the time of advertising therapeutic goods, the advertising must
not be inconsistent with the public health campaign
• Campaigns can be current but not necessarily active – e.g.
respiratory hygiene campaigns only run in cold & flu season
• Guidance contains more information on establishing current
public health campaigns
84
S.21: Consistency with public health campaigns
Example: There are a
range of current initiatives
in Australia to encourage
responsible alcohol
consumption
NOT COMPLIANT
Drinkers Delight
liver tonic
• improves liver function
• protects the liver from damage from
alcohol consumption – especially on
a big night out!
Cheers!
85
S.21: Consistency with public health campaigns
Example: National
tobacco campaign –
an ongoing campaign
to promote the quit
smoking message
across the national
population
NOT COMPLIANT
SmokeProtect
Natural antioxidants to protect the lungs
from toxins in cigarette smoke
Just one daily dose
provides all the protection you need
86
Part 3 - Requirements when
advertising particular types of
therapeutic goods
87
S.22 - Application
• Part 3 of the Code does not apply to:
– Labels (as defined in s.3 of the Act)
– Consumer medicine information leaflets (patient information
documents as defined in Regs)
– Patient information leaflets (implantable medical devices – see
s.4 - Definitions)
• These documents can still be considered promotional and have to
comply with all other relevant Code provisions
88
S.23 – Complementary medicines
If an advertisement for a complementary medicine includes
a claim or group of claims based on evidence of a history of
traditional use, the reliance on this traditional use and
paradigm must be disclosed in the advertisement and the
disclosure must be prominently displayed or communicated
in the advertisement.
• This provision provides clarity around expectations for
medicines advertised on the basis of traditional use
89
S.23 – Complementary medicines
• Some medicines rely on multiple paradigms – if this is the
case, they need to be included in the ad.
• Example:
 Traditionally used in Ayurvedic medicine to relieve
sleeplessness. Traditionally used in western herbal medicine
to soothe restlessness.
 Ingredient X is traditionally used in Ayurvedic and western
herbal medicine to soothe sleeplessness and restlessness. 90
S.24 – Analgesics
• Oral analgesic ads must prominently display or communicate:
INCORRECT USE COULD BE HARMFUL
• The ad must not imply that analgesic consumption is safe or they can
relax, relieve tension, sedate or stimulate
• Definition of analgesic in s.4 – excludes combinations of analgesic
and other ingredients for self limiting conditions
• Needs to be used in conjunction with other mandatories
• For radio ads 15s or less - FOLLOW THE DIRECTIONS FOR USE.
INCORRECT USE COULD BE HARMFUL. 91
S.25 – Vitamins and minerals
An advertisement for vitamin or mineral supplements must
not claim or imply that the supplements:
• (a) are a substitute for good nutrition or a balanced diet;
or
• (b) are in any way superior to or more beneficial than
dietary nutrients.
92
S.26 – Goods for weight management
(1) An advertisement for therapeutic goods containing any claim
relating to weight management must balance the claims with
the need for a healthy energy-controlled diet and physical
activity.
(2) Advertising of therapeutic goods containing any claim relating
to weight management must not include any reference or
depiction suggesting that the therapeutic goods will correct or
reverse the effects of overeating or over-consumption of any
food or drink.
93
S.26 – Weight management
(3) An advertisement for therapeutic goods containing any claim
relating to weight management must not:
(a) feature individuals in images or visual representations;
or
(b) use individuals’ statistics or testimonials; unless the
results achieved by those individuals from the use of the
goods would be expected to be achieved on average by
users of the goods.
94
S.27 – Sunscreens
For an ad for a therapeutic good that is or contains a sunscreen
that is claimed to prevent sunburn or skin cancer, the ad must:
• depict sunscreens as being only one part of sun protection; and
• include statements or visual representations, prominently
displayed or communicated, to the effect that:
– prolonged high-risk sun exposure should be avoided; and
– frequent re-application or use in accordance with directions is
required for effective sun protection.
95
Part 4 – Restricted and
prohibited representations
96
Prohibited and Restricted Representations
• The Act makes it a criminal offence, and provides civil penalties,
where an advertiser makes reference certain conditions (explicitly,
or by implication) in advertising of therapeutic goods without prior
approval:
– S. 42DL(7) and 42DLB(4) – restricted representations
– S. 42DL(5) and 42DLB(2) – prohibited representations
• The Act also provides that the Secretary may approve the use of
these representations under certain circumstances (s.42DF and
s.42DK)
97
s.29(1)(a) – medically accepted to be
a form requiring
diagnosis, treatment or supervision
by a suitably qualified health
professional?
s.29(1)(a) - Once medically diagnosed, is it
medically accepted to be suitable
for self-treatment and management?
s.29(1)(b) - Is there a diagnostic/screening, or
other kind of test for the form which requires
medical interpretation or follow-up? The form IS a
serious form
NOT a serious form
NO
YES YES
NO
NO
YES
98
Restricted representations
• A range of examples of what are and are not considered
serious conditions are provided in the Guidance.
• The conditions included in the Guidance make for a fairly
easy assessment of whether or not they need to be
medically diagnosed.
• Where the serious condition is implied by the
representation, this may be more difficult to assess
99
Group discussion:
Which conditions are prohibited or
restricted representations?
100
Permitted restricted representations
• TGA has permitted the use of certain restricted representations by
all advertisers of therapeutic goods, where the ad and product
meets the characteristics and requirements specified.
• Permitted restricted representations include:
– Neural tube defect risk reduction in pregnancy when advertising
medicines with at least 400µg folic acid/day
– representations about sleep apnoea, Obstructive Sleep Apnoea
(OSA) and Central Sleep Apnea/Apnoea (CSA) in relation to
Continuous Positive Airway Pressure (CPAP) equipment
101
Restricted
representation
approvals and
permissions
are published
on the TGA
website
102
S.30 - Prohibited representations
• Representations (express or implied) about the treatment, cure, prevention,
diagnosis (including screening), monitoring or susceptibility of, or pre-
disposition to:
– Neoplastic diseases (i.e. all types of cancer)
– Sexually transmitted disease
– HIV/AIDS
– Hepatitis C virus
– Mental illness
• Abortifacient action
103
Using prohibited representations
• The use of a prohibited representation may be authorised where it
is necessary for either:
– Public health interest; or
– The appropriate use of the goods (packaging & labelling only)
• There is no process for applying to use prohibited representations
– TGA will identify where it is needed
• Representations about preventing transmission of
STDs/HIV/AIDS and prevention of skin cancer through sunscreen
use are prohibited representations but will be permitted
104
Summary & finding
more information
105
Top tips for compliant 2019 advertising
 Ensure ads contain the correct mandatory statements and
information with appropriate prominence
 Check advertising for complementary medicines, analgesics,
vitamins, weight loss products and sunscreens carefully to
ensure full compliance with the express provisions
 Don’t use advertising with references to diseases, conditions,
ailments or defects before checking if you need restricted
representation approval
106
Top tips for compliant 2019 advertising
 Ensure testimonials, endorsements and scientific
representations fully comply with clarified requirements
 Don’t use advertising that is inconsistent with the product’s
ARTG entry, directions, or instructions for use
 Don’t use advertising that encourages people to delay seeking
medical advice or cease prescribed therapies
 Don’t use advertising that conflicts with public health campaigns
107
More information on the 2018 Code
• The 2018 Code:
– Search “Advertising Code” on the TGA website
• The 2018 Code guidance
– Available from the Advertising Code page on the TGA website
• The 2018 Code explanatory statement
– Open the 2018 Code and click on ‘Explanatory statement’ button
• More face to face and webinar education activities planned
• Online training module planned
108
More general advertising information
• Advertising hub – www.tga.gov.au/advertising-hub
– Online training module – more to come
– Australian Regulatory Guidelines for Advertising Therapeutic
Goods
• Regulatory affairs consultant / legal advice
• TGA Online advertising inquiry form -
https://compliance.tga.gov.au/advertising-enquiry/
109
TGA website www.tga.gov.au
TGA Advertising Hub https://www.tga.gov.au/advertising-hub
• Facebook https://www.facebook.com/TGAgovau/
Twitter https://twitter.com/TGAgovau
youtube https://www.youtube.com/channel/UCem9INJbMSOeW1Ry9cNbucw
More on TGA visit……………..
110
Questions on the
2018 Code?
111
112

More Related Content

What's hot

TGOs versus Pharmacopoeias: Do I have a choice?
TGOs versus Pharmacopoeias: Do I have a choice?TGOs versus Pharmacopoeias: Do I have a choice?
TGOs versus Pharmacopoeias: Do I have a choice?TGA Australia
 
Registration procedure of drugs in european union
Registration procedure of drugs in european unionRegistration procedure of drugs in european union
Registration procedure of drugs in european unionbdvfgbdhg
 
Sponsor Information and Training day Session B3 - Medical Devices: Advertising
Sponsor Information and Training day Session B3 - Medical Devices: AdvertisingSponsor Information and Training day Session B3 - Medical Devices: Advertising
Sponsor Information and Training day Session B3 - Medical Devices: AdvertisingTGA Australia
 
Regulatory Reform - Are we heading in the right direction?
Regulatory Reform - Are we heading in the right direction?Regulatory Reform - Are we heading in the right direction?
Regulatory Reform - Are we heading in the right direction?TGA Australia
 
Update on the therapeutic goods advertising reforms - webinar
Update on the therapeutic goods advertising reforms - webinarUpdate on the therapeutic goods advertising reforms - webinar
Update on the therapeutic goods advertising reforms - webinarTGA Australia
 
Pharmacovigilance evmpd submission
Pharmacovigilance evmpd submissionPharmacovigilance evmpd submission
Pharmacovigilance evmpd submissioneCTDconsultancy
 
Manufacturing Quality Branch – 2015 Achievements and Challenges
Manufacturing Quality Branch – 2015 Achievements and ChallengesManufacturing Quality Branch – 2015 Achievements and Challenges
Manufacturing Quality Branch – 2015 Achievements and ChallengesTGA Australia
 
Best Practices in the Field of Serialization and Safe Supply Chain
Best Practices in the Field of Serialization and Safe Supply Chain Best Practices in the Field of Serialization and Safe Supply Chain
Best Practices in the Field of Serialization and Safe Supply Chain László Árvai
 
TGA presentation: The role of the TGA
TGA presentation: The role of the TGATGA presentation: The role of the TGA
TGA presentation: The role of the TGATGA Australia
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in euRajaniKarpur
 
Vitafoods eu clinical trials regulation
Vitafoods   eu clinical trials regulationVitafoods   eu clinical trials regulation
Vitafoods eu clinical trials regulationAxon Lawyers
 
Vitafoods - Alternative Sources of Protein
Vitafoods - Alternative Sources of Protein Vitafoods - Alternative Sources of Protein
Vitafoods - Alternative Sources of Protein Axon Lawyers
 
Building on Drug Safety - the new EU guidelines May 2012
Building on Drug Safety - the new EU guidelines May 2012Building on Drug Safety - the new EU guidelines May 2012
Building on Drug Safety - the new EU guidelines May 2012Doctors.net.uk
 
Regulatory guidelines of Australia
Regulatory guidelines of AustraliaRegulatory guidelines of Australia
Regulatory guidelines of Australianandiniwarier93
 
Vitafoods B2C communication in the funtional food
 Vitafoods B2C communication in the funtional food  Vitafoods B2C communication in the funtional food
Vitafoods B2C communication in the funtional food Axon Lawyers
 

What's hot (20)

TGOs versus Pharmacopoeias: Do I have a choice?
TGOs versus Pharmacopoeias: Do I have a choice?TGOs versus Pharmacopoeias: Do I have a choice?
TGOs versus Pharmacopoeias: Do I have a choice?
 
Registration procedure of drugs in european union
Registration procedure of drugs in european unionRegistration procedure of drugs in european union
Registration procedure of drugs in european union
 
Sponsor Information and Training day Session B3 - Medical Devices: Advertising
Sponsor Information and Training day Session B3 - Medical Devices: AdvertisingSponsor Information and Training day Session B3 - Medical Devices: Advertising
Sponsor Information and Training day Session B3 - Medical Devices: Advertising
 
Regulatory Reform - Are we heading in the right direction?
Regulatory Reform - Are we heading in the right direction?Regulatory Reform - Are we heading in the right direction?
Regulatory Reform - Are we heading in the right direction?
 
Session1: Patrick Deboyser, European Union
Session1: Patrick Deboyser, European UnionSession1: Patrick Deboyser, European Union
Session1: Patrick Deboyser, European Union
 
Update on the therapeutic goods advertising reforms - webinar
Update on the therapeutic goods advertising reforms - webinarUpdate on the therapeutic goods advertising reforms - webinar
Update on the therapeutic goods advertising reforms - webinar
 
2015_PV support by DADA
2015_PV support by DADA2015_PV support by DADA
2015_PV support by DADA
 
Pharmacovigilance evmpd submission
Pharmacovigilance evmpd submissionPharmacovigilance evmpd submission
Pharmacovigilance evmpd submission
 
Manufacturing Quality Branch – 2015 Achievements and Challenges
Manufacturing Quality Branch – 2015 Achievements and ChallengesManufacturing Quality Branch – 2015 Achievements and Challenges
Manufacturing Quality Branch – 2015 Achievements and Challenges
 
Best Practices in the Field of Serialization and Safe Supply Chain
Best Practices in the Field of Serialization and Safe Supply Chain Best Practices in the Field of Serialization and Safe Supply Chain
Best Practices in the Field of Serialization and Safe Supply Chain
 
TGA presentation: The role of the TGA
TGA presentation: The role of the TGATGA presentation: The role of the TGA
TGA presentation: The role of the TGA
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in eu
 
Vitafoods eu clinical trials regulation
Vitafoods   eu clinical trials regulationVitafoods   eu clinical trials regulation
Vitafoods eu clinical trials regulation
 
Vitafoods - Alternative Sources of Protein
Vitafoods - Alternative Sources of Protein Vitafoods - Alternative Sources of Protein
Vitafoods - Alternative Sources of Protein
 
Regulatory Procedures
Regulatory ProceduresRegulatory Procedures
Regulatory Procedures
 
Building on Drug Safety - the new EU guidelines May 2012
Building on Drug Safety - the new EU guidelines May 2012Building on Drug Safety - the new EU guidelines May 2012
Building on Drug Safety - the new EU guidelines May 2012
 
AMNOG
AMNOGAMNOG
AMNOG
 
Regulatory guidelines of Australia
Regulatory guidelines of AustraliaRegulatory guidelines of Australia
Regulatory guidelines of Australia
 
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...
 
Vitafoods B2C communication in the funtional food
 Vitafoods B2C communication in the funtional food  Vitafoods B2C communication in the funtional food
Vitafoods B2C communication in the funtional food
 

Similar to TGA presentation: Therapeutic Goods Advertising Code (No. 2) 2018 - The Code basics - 20 November

Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
Presentation: Therapeutic Goods Advertising Code (No. 2) 2018Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Australia
 
Therapeutic Goods Advertising Code (No. 2) 2018
Therapeutic Goods Advertising Code (No. 2) 2018Therapeutic Goods Advertising Code (No. 2) 2018
Therapeutic Goods Advertising Code (No. 2) 2018TGA Australia
 
TGA presentation: What pharmacies need to know about advertising therapeutic ...
TGA presentation: What pharmacies need to know about advertising therapeutic ...TGA presentation: What pharmacies need to know about advertising therapeutic ...
TGA presentation: What pharmacies need to know about advertising therapeutic ...TGA Australia
 
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Australia
 
Devices Sponsor Information Day: 5 - Post-market - Advertising therapeutic go...
Devices Sponsor Information Day: 5 - Post-market - Advertising therapeutic go...Devices Sponsor Information Day: 5 - Post-market - Advertising therapeutic go...
Devices Sponsor Information Day: 5 - Post-market - Advertising therapeutic go...TGA Australia
 
Presentation: Advertising cosmetic injectables - Complying with the therapeut...
Presentation: Advertising cosmetic injectables - Complying with the therapeut...Presentation: Advertising cosmetic injectables - Complying with the therapeut...
Presentation: Advertising cosmetic injectables - Complying with the therapeut...TGA Australia
 
TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...
TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...
TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...TGA Australia
 
Presentation for webinar: The new advertising code - where are we at? 12 jun...
Presentation for webinar:  The new advertising code - where are we at? 12 jun...Presentation for webinar:  The new advertising code - where are we at? 12 jun...
Presentation for webinar: The new advertising code - where are we at? 12 jun...TGA Australia
 
TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?TGA Australia
 
Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers TGA Australia
 
Reporting of Medicine Shortages
Reporting of Medicine ShortagesReporting of Medicine Shortages
Reporting of Medicine ShortagesTGA Australia
 
Presentation: Advertising Therapeutic Goods to Consumers
Presentation: Advertising Therapeutic Goods to ConsumersPresentation: Advertising Therapeutic Goods to Consumers
Presentation: Advertising Therapeutic Goods to ConsumersTGA Australia
 
Presentation for roadshow: The new advertising code - where are we at? 13 jun...
Presentation for roadshow: The new advertising code - where are we at? 13 jun...Presentation for roadshow: The new advertising code - where are we at? 13 jun...
Presentation for roadshow: The new advertising code - where are we at? 13 jun...TGA Australia
 
Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...TGA Australia
 
Presentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reformsPresentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reformsTGA Australia
 
Scheduling working group meeting two, 6 March 2018
Scheduling working group meeting two, 6 March 2018Scheduling working group meeting two, 6 March 2018
Scheduling working group meeting two, 6 March 2018TGA Australia
 
VOLUME 9A ppt.pptx
VOLUME 9A ppt.pptxVOLUME 9A ppt.pptx
VOLUME 9A ppt.pptxAartiVats5
 
Presentation: CMA Advertising Seminar
Presentation: CMA Advertising SeminarPresentation: CMA Advertising Seminar
Presentation: CMA Advertising SeminarTGA Australia
 
Marketplace 101.pptx
Marketplace 101.pptxMarketplace 101.pptx
Marketplace 101.pptxRohBudianto2
 

Similar to TGA presentation: Therapeutic Goods Advertising Code (No. 2) 2018 - The Code basics - 20 November (20)

Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
Presentation: Therapeutic Goods Advertising Code (No. 2) 2018Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
 
Therapeutic Goods Advertising Code (No. 2) 2018
Therapeutic Goods Advertising Code (No. 2) 2018Therapeutic Goods Advertising Code (No. 2) 2018
Therapeutic Goods Advertising Code (No. 2) 2018
 
TGA presentation: What pharmacies need to know about advertising therapeutic ...
TGA presentation: What pharmacies need to know about advertising therapeutic ...TGA presentation: What pharmacies need to know about advertising therapeutic ...
TGA presentation: What pharmacies need to know about advertising therapeutic ...
 
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
 
Devices Sponsor Information Day: 5 - Post-market - Advertising therapeutic go...
Devices Sponsor Information Day: 5 - Post-market - Advertising therapeutic go...Devices Sponsor Information Day: 5 - Post-market - Advertising therapeutic go...
Devices Sponsor Information Day: 5 - Post-market - Advertising therapeutic go...
 
Presentation: Advertising cosmetic injectables - Complying with the therapeut...
Presentation: Advertising cosmetic injectables - Complying with the therapeut...Presentation: Advertising cosmetic injectables - Complying with the therapeut...
Presentation: Advertising cosmetic injectables - Complying with the therapeut...
 
TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...
TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...
TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...
 
Presentation for webinar: The new advertising code - where are we at? 12 jun...
Presentation for webinar:  The new advertising code - where are we at? 12 jun...Presentation for webinar:  The new advertising code - where are we at? 12 jun...
Presentation for webinar: The new advertising code - where are we at? 12 jun...
 
TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?
 
Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers
 
Reporting of Medicine Shortages
Reporting of Medicine ShortagesReporting of Medicine Shortages
Reporting of Medicine Shortages
 
Presentation: Advertising Therapeutic Goods to Consumers
Presentation: Advertising Therapeutic Goods to ConsumersPresentation: Advertising Therapeutic Goods to Consumers
Presentation: Advertising Therapeutic Goods to Consumers
 
Presentation for roadshow: The new advertising code - where are we at? 13 jun...
Presentation for roadshow: The new advertising code - where are we at? 13 jun...Presentation for roadshow: The new advertising code - where are we at? 13 jun...
Presentation for roadshow: The new advertising code - where are we at? 13 jun...
 
Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...
 
Presentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reformsPresentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reforms
 
Scheduling working group meeting two, 6 March 2018
Scheduling working group meeting two, 6 March 2018Scheduling working group meeting two, 6 March 2018
Scheduling working group meeting two, 6 March 2018
 
VOLUME 9A ppt.pptx
VOLUME 9A ppt.pptxVOLUME 9A ppt.pptx
VOLUME 9A ppt.pptx
 
Presentation: CMA Advertising Seminar
Presentation: CMA Advertising SeminarPresentation: CMA Advertising Seminar
Presentation: CMA Advertising Seminar
 
medical-device-forum.pptx
medical-device-forum.pptxmedical-device-forum.pptx
medical-device-forum.pptx
 
Marketplace 101.pptx
Marketplace 101.pptxMarketplace 101.pptx
Marketplace 101.pptx
 

More from TGA Australia

Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
 
The challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devicesThe challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devicesTGA Australia
 
Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch TGA Australia
 
Consumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI templateConsumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI templateTGA Australia
 
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...TGA Australia
 
Improved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future stateImproved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future stateTGA Australia
 
Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...TGA Australia
 
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...TGA Australia
 
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
 
Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
 
Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
 
SME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory mazeSME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory mazeTGA Australia
 
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA Australia
 
Presentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchPresentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
 
Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...TGA Australia
 
Webinar presentation: Consultation on reforms to the generic medicine market ...
Webinar presentation: Consultation on reforms to the generic medicine market ...Webinar presentation: Consultation on reforms to the generic medicine market ...
Webinar presentation: Consultation on reforms to the generic medicine market ...TGA Australia
 
Presentation: Software as a Medical Device: Regulatory insights and Q & A
Presentation: Software as a Medical Device: Regulatory insights and Q & APresentation: Software as a Medical Device: Regulatory insights and Q & A
Presentation: Software as a Medical Device: Regulatory insights and Q & ATGA Australia
 
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...TGA Australia
 

More from TGA Australia (20)

Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirements
 
The challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devicesThe challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devices
 
Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch
 
Consumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI templateConsumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI template
 
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
 
Improved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future stateImproved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future state
 
Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...
 
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
 
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation Branch
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation Branch
 
Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1
 
Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2
 
SME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory mazeSME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory maze
 
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
 
Presentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchPresentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access Branch
 
Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...
 
Webinar presentation: Consultation on reforms to the generic medicine market ...
Webinar presentation: Consultation on reforms to the generic medicine market ...Webinar presentation: Consultation on reforms to the generic medicine market ...
Webinar presentation: Consultation on reforms to the generic medicine market ...
 
Presentation: Software as a Medical Device: Regulatory insights and Q & A
Presentation: Software as a Medical Device: Regulatory insights and Q & APresentation: Software as a Medical Device: Regulatory insights and Q & A
Presentation: Software as a Medical Device: Regulatory insights and Q & A
 
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
 

Recently uploaded

VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escorts
VIP Call Girls Indore Kirti 💚😋  9256729539 🚀 Indore EscortsVIP Call Girls Indore Kirti 💚😋  9256729539 🚀 Indore Escorts
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escortsaditipandeya
 
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...Miss joya
 
Call Girls Darjeeling Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Darjeeling Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Darjeeling Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Darjeeling Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Bangalore Call Girls Hebbal Kempapura Number 7001035870 Meetin With Bangalor...
Bangalore Call Girls Hebbal Kempapura Number 7001035870  Meetin With Bangalor...Bangalore Call Girls Hebbal Kempapura Number 7001035870  Meetin With Bangalor...
Bangalore Call Girls Hebbal Kempapura Number 7001035870 Meetin With Bangalor...narwatsonia7
 
VIP Call Girls Pune Vani 9907093804 Short 1500 Night 6000 Best call girls Ser...
VIP Call Girls Pune Vani 9907093804 Short 1500 Night 6000 Best call girls Ser...VIP Call Girls Pune Vani 9907093804 Short 1500 Night 6000 Best call girls Ser...
VIP Call Girls Pune Vani 9907093804 Short 1500 Night 6000 Best call girls Ser...Miss joya
 
Bangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% SafeBangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% Safenarwatsonia7
 
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoy
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night EnjoyCall Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoy
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoybabeytanya
 
Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...
Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...
Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...Miss joya
 
Artifacts in Nuclear Medicine with Identifying and resolving artifacts.
Artifacts in Nuclear Medicine with Identifying and resolving artifacts.Artifacts in Nuclear Medicine with Identifying and resolving artifacts.
Artifacts in Nuclear Medicine with Identifying and resolving artifacts.MiadAlsulami
 
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...narwatsonia7
 
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...narwatsonia7
 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escortsvidya singh
 
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...Miss joya
 
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Low Rate Call Girls Patna Anika 8250192130 Independent Escort Service Patna
Low Rate Call Girls Patna Anika 8250192130 Independent Escort Service PatnaLow Rate Call Girls Patna Anika 8250192130 Independent Escort Service Patna
Low Rate Call Girls Patna Anika 8250192130 Independent Escort Service Patnamakika9823
 
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...astropune
 
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune) Girls Service
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune)  Girls ServiceCALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune)  Girls Service
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune) Girls ServiceMiss joya
 
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort ServicePremium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Servicevidya singh
 

Recently uploaded (20)

Russian Call Girls in Delhi Tanvi ➡️ 9711199012 💋📞 Independent Escort Service...
Russian Call Girls in Delhi Tanvi ➡️ 9711199012 💋📞 Independent Escort Service...Russian Call Girls in Delhi Tanvi ➡️ 9711199012 💋📞 Independent Escort Service...
Russian Call Girls in Delhi Tanvi ➡️ 9711199012 💋📞 Independent Escort Service...
 
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escorts
VIP Call Girls Indore Kirti 💚😋  9256729539 🚀 Indore EscortsVIP Call Girls Indore Kirti 💚😋  9256729539 🚀 Indore Escorts
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escorts
 
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
 
Call Girls Darjeeling Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Darjeeling Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Darjeeling Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Darjeeling Just Call 9907093804 Top Class Call Girl Service Available
 
Bangalore Call Girls Hebbal Kempapura Number 7001035870 Meetin With Bangalor...
Bangalore Call Girls Hebbal Kempapura Number 7001035870  Meetin With Bangalor...Bangalore Call Girls Hebbal Kempapura Number 7001035870  Meetin With Bangalor...
Bangalore Call Girls Hebbal Kempapura Number 7001035870 Meetin With Bangalor...
 
VIP Call Girls Pune Vani 9907093804 Short 1500 Night 6000 Best call girls Ser...
VIP Call Girls Pune Vani 9907093804 Short 1500 Night 6000 Best call girls Ser...VIP Call Girls Pune Vani 9907093804 Short 1500 Night 6000 Best call girls Ser...
VIP Call Girls Pune Vani 9907093804 Short 1500 Night 6000 Best call girls Ser...
 
Bangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% SafeBangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% Safe
 
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoy
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night EnjoyCall Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoy
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoy
 
Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...
Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...
Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...
 
Artifacts in Nuclear Medicine with Identifying and resolving artifacts.
Artifacts in Nuclear Medicine with Identifying and resolving artifacts.Artifacts in Nuclear Medicine with Identifying and resolving artifacts.
Artifacts in Nuclear Medicine with Identifying and resolving artifacts.
 
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
 
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Servicesauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
 
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
 
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
 
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
 
Low Rate Call Girls Patna Anika 8250192130 Independent Escort Service Patna
Low Rate Call Girls Patna Anika 8250192130 Independent Escort Service PatnaLow Rate Call Girls Patna Anika 8250192130 Independent Escort Service Patna
Low Rate Call Girls Patna Anika 8250192130 Independent Escort Service Patna
 
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
 
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune) Girls Service
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune)  Girls ServiceCALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune)  Girls Service
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune) Girls Service
 
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort ServicePremium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
 

TGA presentation: Therapeutic Goods Advertising Code (No. 2) 2018 - The Code basics - 20 November

  • 1. Therapeutic Goods Advertising Code (No. 2) 2018 The Code basics Leanne McCauley & Alexandra Dance Advertising Education and Assurance Section Regulatory Education and Compliance Branch Regulatory Practice and Support Division Health Products Regulation Group 20 November 2018
  • 2. Website and link references • Details of the TGA’s advertising complaints handling framework has been published: https://www.tga.gov.au/publication/complaints-handling-advertising-therapeutic-goods-australian-public • TGA statement on its approach to compliance and enforcement discretion in the changeover to 2018 Code: https://www.tga.gov.au/therapeutic-goods-advertising-update-29-october-2018 • Advertising hub – www.tga.gov.au/advertising-hub – Online training module – more to come – Australian Regulatory Guidelines for Advertising Therapeutic Goods • Regulatory affairs consultant / legal advice • TGA Online advertising inquiry form - https://compliance.tga.gov.au/advertising-enquiry/ 1
  • 3. Role of the Advertising Code • The Code is the cornerstone of the advertising framework –Requires that advertising supports appropriate use of therapeutic goods and does not mislead or deceive • Current version is 2015 Code – until 31 December 2018 • The Code was revised to provide clarity and more objective tests to support sanctions and penalties 2
  • 4. Compliance with Advertising Code • Advertising to the public for therapeutic goods MUST comply with the Advertising Code • Requirement to comply with the Code is specified through a criminal offence and civil penalty provision in the Act: –Section 42DM – criminal offence –Section 42DMA – civil penalty • For an ad to be approved under the Regulations, the delegate must be satisfied that it complies with the Code 3
  • 5. About the 2018 Code • The 2018 Code was made on 31 October 2018, to take effect on 1 January 2019 • Principles underpinning 2015 and 2018 Codes are similar • The 2018 Code is supported by specific guidance 4
  • 6. Code version for pre-approvals • Ads for medicines to appear in specified media require pre- approval under Regulation 5G • For pre-approval decisions made: –On or after 1 January 2019: 2018 Code applied –On or before 31 December 2018: 2015 Code applied • You must allow time for the process, any revisions and Christmas shut downs 5
  • 7. Code version applied in compliance • For ads with current approval: version of Code approved under • For ads (other than pre-approved ads) that occurred: Advertising occurred Assessed against On or after 1 January 2019 2018 Code Before 1 January 2019 and is no longer occurring 2015 Code Before 1 January 2019 and is still occurring 2018 Code 6
  • 8. Compliance approach • Details of the TGA’s advertising complaints handling framework has been published: https://www.tga.gov.au/publication/complaints-handling- advertising-therapeutic-goods-australian-public • TGA statement on its approach to compliance and enforcement discretion in the changeover to 2018 Code: https://www.tga.gov.au/therapeutic-goods-advertising- update-29-october-2018 7
  • 9. Scheduling of medicines • No advertising to consumers • S3 – only Appendix H can be advertised • Can be advertised to consumers • S8 - Drugs of Dependence – by prescription • S4 - By prescription only • S3 - Pharmacist only – behind the counter • S2 - Pharmacy only • Unscheduled – General sales item 8
  • 10. The Therapeutic Goods Advertising Code 2018 in detail 9
  • 11. Structure of the 2018 Code • Part 1 – Preliminary – definitions, object, application • Part 2 – General requirements for advertising therapeutic goods • Part 3 – Specific rules relating to particular therapeutic goods • Part 4 – Prohibited & restricted representations • Schedule 1 – Medicines with specific health warnings • Schedule 2 – Advertising to children • Schedule 3 – Samples • Schedule 4 – Price information • Schedule 5 – Repeals 10
  • 12. Part 1 - Preliminary 11
  • 13. Section 4 - Definitions • It is important to read the Code in conjunction with the Act and the Therapeutic Goods Regulations 1990 –Terms that are not defined in the Code may be defined in the Act and Regulations (e.g. ‘advertise’) • Most Code definitions straightforward but there are some that we will explore in detail: –Health warning –Prominently displayed or communicated 12
  • 14. What are health warnings? • In some cases, health warnings need to be included in ads • Concept of ‘health warning’ is defined in s.4 of the Code • The purpose of health warnings is to alert consumers to information that will be critical to the consumer's assessment of whether the advertised product is right for them before purchase 13
  • 15. Health warning definition - medicines • Health warnings for medicines are prescribed in Schedule 1 of the Code • Schedule 1 health warnings are: – an exhaustive list but may be updated from time to time – based on RASML, permitted ingredients determination, TGO69 and TGO92 – divided into different parts for warnings for registered medicines, listed medicines and both types of medicines 14
  • 16. Example of medicine health warnings 1. Ingredients 2. Circumstances 3. Health warning Hydroxyanthracene derivatives such as those from: • Aloe • Buckthorn • Cascara • Frangula • Rhubarb • Senna In preparations for oral use where the MRDD contains MORE than 10mg Do not use if you have abdominal pain, nausea, vomiting or diarrhoea Ibuprofen/Paracetamol combinations In preparations for oral use Do not use if you have a stomach ulcer, impaired kidney function, heart failure, allergic to anti inflammatory medicines, pregnant or trying to become pregnant 15
  • 17. Health warning definition – devices/OTGs …a statement that is required under the Act or Regulations or Medical Devices Regulations to be included on the label or in instructions for use that warns that a person who takes or uses the device or goods as intended may: (i) die; or (ii) require hospitalisation or a longer period of hospitalisation than would be required if the person had not taken or used the device or goods; or (iii) require a medical practitioner to treat or prevent injury, disability, incapacity or impairment of any bodily function, organ or structure as a consequence of taking or using the device or goods 16
  • 18. Prominently displayed or communicated ‘prominently displayed or communicated’ is defined as: (a) either: (i) for a visual statement-standing out so as to be easily read from a reasonable viewing distance for the particular media type in the context in which the advertisement is intended to be viewed; or (ii) for a spoken statement-able to be clearly heard and understood; and (b) repeated as often as is necessary to ensure that it is likely to be noticeable for a viewer or listener. 17
  • 19. Section 5 – Object of the Code “...to ensure that the advertising of therapeutic goods to consumers is conducted in a manner that: (a) promotes the safe and proper use of therapeutic goods by minimising their misuse, overuse or underuse; and (b) is ethical and does not mislead or deceive the consumer or create unrealistic expectations about product performance; and (c) supports informed health care choices; and (d) is not inconsistent with current public health campaigns.“ 18
  • 20. Section 6 – Application • Applies to: – The advertising of therapeutic goods (ss.6(1)) – By any person advertising or causing advertising (ss.6(5)) • Does not apply to: – Genuine news (ss.6(6)) by certain bodies (ss.6(7)) – including broadcasters, datacasters and publishers – Advertising directed exclusively to health professionals (ss.6(2)) 19
  • 21. Section 6 – Application • How to apply the Code to a particular advertisement: – consider its likely impact on a reasonable person to whom the advertisement is directed (ss.6(3)) – the total presentation and context of the advertisement is to be taken into account (ss.6(4)) 20
  • 22. Audience advertisement directed to • Advertising may be directed to the public in general or a sub-population • A direction may be made in many forms, including: – An overt statement e.g. “Do you suffer from cold sores?”, “For the relief of psoriasis” – An implied call to capture the attention of a sub-population e.g. for the measurement of blood pressure – The location of the ad e.g. in a magazine for diabetics 21
  • 23. Total presentation & context • Total presentation: the advertisement as a whole • Context includes: – What other information is provided around the advertisement that could change the take-out message? e.g. an editorial on a page opposite the advertisement – Does the environment in which it is displayed have the potential to alter the take-out message? E.g. a billboard ad that is viewed when passing in a car at speed 22
  • 24. Example – reasonable consumer 23
  • 26. Section 6A & 6B – Repeals & transition • Section 6A, by reference to Schedule 5, repeals the 2015 Code and the original 2018 Code • Section 6B allows for a transition period for ads pre- approved under the 2015 Code – i.e. –Complaints about such ads will be assessed against the 2015 Code for the life of the approval 25
  • 27. Section 7 - Price information • Price information – definition in s.4 of Code – relates to prescription medicines and pharmacist-only medicines only • S.42DL(10) of the Act – advertising of prescription medicines to the public prohibited “other than a reference authorised or required by a government or government authority” • Section 7 of the Code authorises the dissemination of price lists that comply with Schedule 4 of the Code – i.e. not an offence under the Act • Schedule 4 replaces Price information code of practice 26
  • 28. Part 2 - Requirements for advertising all therapeutic goods to the public 27
  • 29. Section 8 – Approved ads • Ads for medicines for ‘specified media’ (e.g. free-to-air television, newspaper, billboard) require prior approval under Regulation 5G Arises from offence under section 42C of Act • S.8 requires ads appearing in print media and billboards to display the approval number in the advertisement as set out in ss.8(3) – must be legible 28
  • 30. S.9 – Accuracy: validity & substantiation Advertising for therapeutic goods must satisfy the following: (a) any claims made in the advertising are valid and accurate, and all information presented has been substantiated before the advertising occurs Example: An ad promotes a medical device for identifying allergies from a non-invasive sample from the patient. The advertiser states the claim is supported by a small clinical trial conducted in the 1960s. Subsequent larger studies failed to reproduce the positive findings. The claims are not valid. 29
  • 31. S.9 – Accuracy: truthful & not misleading Advertising for therapeutic goods must satisfy the following: (b) it is truthful, balanced and not misleading or likely to mislead, including in its claims, presentations, representations and comparisons Example: an imaging device is advertised as producing 5 times less radiation than other devices but fails advise that the amount of radiation produced by such devices is very small. It is likely to mislead consumers: • into thinking other imaging devices are harmful • as to the order of magnitude of the difference in radiation produced by the devices – even if the claim is substantiated. 30
  • 32. S.9 – Accuracy: comparisons Advertising for therapeutic goods must satisfy the following: (c) any comparisons made in the advertising between therapeutic goods or classes of therapeutic goods do not directly or indirectly claim that the goods or class of goods being used as the comparator are harmful or ineffectual; Example: A head lice product is promoted as being more effective and safer than the leading brand, which has an ingredient shown to cause birth defects 31
  • 33. S.9 – Accuracy: consistency with ARTG Advertising for therapeutic goods must satisfy the following: (d) if the goods are included in the Register - it is consistent with the entry for the therapeutic goods in relation to that inclusion. Example: A product is included in the ARTG for the relief of pain in adults aged 18-65 only. If the product was promoted for pain relief for children, it would contravene s.9(d). 32
  • 34. S.10 – Effect: support proper use (a) Advertising for therapeutic goods must support the safe and proper use of therapeutic goods by: (i) presenting the goods in accordance with directions or instructions for use; and (ii) not exaggerating product efficacy or performance; Example: A topical preparation for the relief of symptoms of eczema is promoted for oral consumption as it works faster 33
  • 35. S.10 – Effect: delaying appropriate treatment (b) Advertising for therapeutic goods must…not be likely to lead to people delaying necessary medical attention or delaying the use of, or failing to use, treatment prescribed by a medical practitioner; Example: a herbal medicine is promoted as an alternative to antibiotics and people should use it as first line treatment for conjunctivitis and other infections instead of antibiotics 34
  • 36. S.10 – Effect: encourage inappropriate use (c) Advertising for therapeutic goods must not encourage inappropriate or excessive use of the therapeutic goods Example: A medical device for alleviating snoring is promoted for alleviating sleep apnoea. The advertising would be likely to encourage inappropriate use. 35
  • 37. S.10 – Effect: safe or cannot harm (d) Advertising for therapeutic goods must not contain any claim, statement, implication or representation that: (i) the therapeutic goods are safe or that their use cannot cause harm, or that they have no side-effects Example: A herbal medicine is promoted as having a safe mode of action and that millions of people have bought it and there have been no adverse reports. 36
  • 38. S.10 – Effect: sure cure (d) Advertising for therapeutic goods must not contain any claim, statement, implication or representation that… (ii) the therapeutic goods are effective in all cases of a condition or that the outcome from their use is a guaranteed or sure cure; Example: A medical device is promoted as guaranteed to improve lung function by 75% in COPD patients 37
  • 39. S.10 – Effect: miraculous (d) Advertising for therapeutic goods must not contain any claim, statement, implication or representation that… (iii) the therapeutic goods are infallible, unfailing, magical or miraculous; Example: A testimonial on a website for a medicine for relieving cystitis states the product is miraculous and the symptoms were gone within two hours and did not return. 38
  • 40. S.10 – Effect: harmful consequences (d) Advertising for therapeutic goods must not contain any claim, statement, implication or representation that… (iv) harmful consequences may result from the therapeutic goods not being used - unless the claim, statement, implication or representation is permitted under section 42DK of the Act or approved under section 42DF of the Act. Example: An ad for a supplement for 65+ year olds is promoted by stating that retirees won’t be able to continue playing golf and keeping up with their grandkids unless they use the supplement 39
  • 41. Sections 11 - 13 Mandatory information and statements 40
  • 42. Overview: application of sections Section 11 Section 12 Section 13 Ad for S3 (App H) medicine  Ad for non-S3 therapeutic good that allows purchase without seeing the good   (selected items only) Any other ad for non-S3 therapeutic good  Note: other provisions in the Code, including Part 3, will still apply in each case 41
  • 43. S.11: Required statement – S3s • An advertisement for a medicine containing a substance included in Schedule 3 of the Poisons Standard and Appendix H must prominently display or communicate: ASK YOUR PHARMACIST -THEY MUST DECIDE IF THIS PRODUCT IS RIGHT FOR YOU • This is the only mandatory statement required by Part 2 for S3 medicines advertising – Part 3 still applies – e.g. analgesics warning • Does not apply to labels, CMIs or PILs 42
  • 44. Section 12 & 13 requirements Ad must prominently display or communicate: • Basic info about the goods • Important health information (or a prompt to consumers to read it) • Advice to follow directions • A symptom statement (if there are claims about symptoms 43
  • 45. S.12: What must ads contain (goods not available for inspection) • This section is only for ads for goods that are not available for physical examination by the consumer before or at the time of purchase (e.g. internet, mail order marketing) • Does not apply to: – advertisements subject to section 11 – a label, consumer medicine information or a patient information leaflet 44
  • 46. Section 12 mandatories: medicines Type of information Provision and the information required in ad Basic information about the goods • ss.12(3)(a) – (c) – the name of the medicine, dosage form, the quantity of the medicine • ss.12(3)(d) - one or more of the indications for the medicine, as they appear on the medicine’s label • ss.12(3)(e) - a list of certain ingredients – see definition in s.4 Important health information • ss.12(3)(f) – an alert to the consumer to read the label or warnings (as appropriate for the nature of the medicine) Follow the directions statement • ss.12(3)(g) – ‘Follow the directions for use’ or ‘Follow the instructions for use’ from ss.13(6) Symptom statement • ss.12(3)(h) - If there are symptoms claims in ad, include appropriate statement/s from ss.13(7) 45
  • 47. ss.12(3)(f): Important health info for medicines Are there health warnings in Schedule 1 of the Code for the medicine? Do you want to include the health warnings in the ad? USE: ‘This medicine may not be right for you. Read the warnings before purchase’ followed immediately by information about where the health warnings can be found USE: ‘Always read the label’ and the health warnings USE: ‘Always read the label’ NoYes No Yes 46
  • 48. Section 12 mandatories: devices Type of information Provision and the information required in ad Basic information about the goods • ss.12(4)(a) – (b) – an accurate description and a reference to EITHER the trade name or another name for the device • ss.12(4)(c) – the intended purpose or indications for the device as they appear on label or primary packaging • ss.12(4)(d) - a list of the ingredients if applicable Important health information • ss.12(4)(e) – an alert to the consumer to read the label, instructions or warnings (as appropriate for the device) Follow the directions statement • ss.12(4)(f) – ‘Follow the directions for use’ or ‘Follow the instructions for use’ from ss.13(6) as appropriate for the device Symptom statement • ss.12(4)(g) - If there are symptoms claims in ad, include appropriate statement/s from ss.13(7) 47
  • 49. ss.12(4)(e): Important info for devices Are there statements on the label or instructions for use for the device that meet the definition of ‘health warning’ in section 4 of the Code? Do you want to include the health warnings in the ad? USE: ‘This product may not be right for you. Read the warnings before purchase’ followed immediately by information about where the health warnings can be found USE: ‘Always read the label/instructions for use’ and the health warnings USE: ‘Always read the label/instructions for use’ NoYes No Yes 48
  • 50. Section 12 mandatories: OTGs Type of information Provision and the information required in ad Basic information about the goods • ss.12(5)(a) – (b) – an accurate description and a reference to EITHER the trade name or another name for the goods • ss.12(5)(c) – the intended purpose or indications for the goods as they appear on label or primary packaging • ss.12(5)(d) - a list of the ingredients where relevant Important health information • ss.12(5)(e) – an alert to the consumer to read the label, instructions or warnings (as appropriate for the goods) Follow the directions statement • ss.12(5)(f) – ‘Follow the directions for use’ or ‘Follow the instructions for use’ from ss.13(6) as appropriate for the goods Symptom statement • ss.12(5)(g) - If there are symptoms claims in ad, include appropriate statement/s from ss.13(7) 49
  • 51. ss.12(5)(e): Important info for OTGs Are there statements on the label or instructions for use for the goods that meet the definition of ‘health warning’ in section 4 of the Code? Do you want to include the health warnings in the ad? USE: ‘This product may not be right for you. Read the warnings before purchase’ followed immediately by information about where the health warnings can be found USE: ‘Always read the label/instructions for use’ and the health warnings USE: ‘Always read the label/instructions for use’ NoYes No Yes 50
  • 53. Example – Bean’s Tonic internet marketing 52
  • 54. S.13: What must ads contain (general) • This section is only for ads that: – are for goods other than Schedule 3 medicines (see s.13(1)(d) - section 11 applies to these) – do not facilitate purchase of the goods without the consumer being able to inspect them (see s.13(1)(e) - section 12 applies to these) • This section does not apply to labels, consumer medicine information or a patient information leaflet (s.13(1)(a) & (b)) 53
  • 55. S.13: What must ads contain (general) • This section also does not apply to picture/price/point of sale ads (see s.13(1)(c)) – i.e.: –an advertisement displaying only the name or picture of therapeutic goods or their price or point of sale, or any combination of these, provided the advertisement does not contain or imply a claim relating to therapeutic use, or any other representation 54
  • 56. Section 13 mandatories: medicines Type of information Provision and the information required in ad Basic information about the goods • ss.13(2)(a) – (b) – a reference to the trade name of the medicine and one or more of the indications as they appear on label Important health information • ss.13(2)(c) – an alert to the consumer to read the label, instructions or warnings (as appropriate for the goods) Follow the directions statement • ss.13(6) – ‘Follow the directions for use’ or ‘Follow the instructions for use’ as appropriate for the goods Symptom statement • ss.13(7) - If there are symptoms claims in ad, include appropriate statement/s 55
  • 57. ss.13(2)(c): Important info for medicines Are there health warnings in Schedule 1 of the Code for the medicine? Do you want to include the health warnings in the ad? USE: ‘This medicine may not be right for you. Read the label before purchase’ USE: ‘Always read the label’ and the health warnings USE: ‘Always read the label’ NoYes No Yes 56
  • 58. Section 13 mandatories: devices Type of information Provision and the information required in ad Basic information about the goods • ss.13(3)(a) – (b) – an accurate description and a reference to EITHER the trade name or another name for the device • ss.13(3)(c) – the intended purpose or indications for the device Important health information • ss.13(3)(d) – an alert to the consumer to read the label, instructions or warnings (as appropriate for the device) Follow the directions statement • ss.13(6) – ‘Follow the directions for use’ or ‘Follow the instructions for use’ as appropriate for the device Symptom statement • ss.13(7) - If there are symptoms claims in ad, include appropriate statement/s 57
  • 59. ss.13(3)(d): Important info for devices Are there statements on the label or instructions for use for the device that meet the definition of ‘health warning’ in section 4? Do you want to include the health warnings in the ad? USE: ‘This product may not be right for you. Read the label/instructions for use before purchase’ depending on whether there is a label visible on primary pack USE: ‘Always read the label/instructions for use’ and the health warnings USE: ‘Always read the label/instructions for use’ NoYes No Yes 58
  • 60. Section 13 mandatories: OTGs Type of information Provision and the information required in ad Basic information about the goods • ss.13(4)(a) – (b) – an accurate description and a reference to EITHER the trade name or another name for the goods • ss.13(4)(c) – the intended purpose or indications for the goods Important health information • ss.13(4)(d) – an alert to the consumer to read the label or instructions (as appropriate for the goods) Follow the directions statement • ss.13(6) – ‘Follow the directions for use’ or ‘Follow the instructions for use’ as appropriate for the goods Symptom statement • ss.13(7) - If there are symptoms claims in ad, include appropriate statement/s 59
  • 61. ss.13(4)(d): Important info for OTGs Are there statements on the label or instructions for use for the goods that meet the definition of ‘health warning’ in section 4? Do you want to include the health warnings in the ad? USE: ‘This product may not be right for you. Read the label/instructions for use before purchase’ depending on whether there is a label visible on primary pack USE: ‘Always read the label/instructions for use’ and the health warnings USE: ‘Always read the label/instructions for use’ NoYes No Yes 60
  • 62. Exemptions from parts of section 13: short form ads • “Short form ads” are: –Radio commercials 15 seconds or less duration –Text-only ads of 300 characters or less with no ability to include pictures, logos or other imagery • Short form ads are exempt from: –The calls to action – ‘Always read the label’ etc –Symptoms statement (ss.13(6)) 61
  • 64. Example 1 – Bean’s Tonic An example of prominently displayed mandatories for a medicine without health warnings 63
  • 65. Example 2 – Bean’s Tonic An example of prominently displayed mandatories for a medicine with health warnings - using mandatories option 1 and 2 64
  • 66. Example 4 – Bean’s Tonic Will not be compliant under the Code 65
  • 67. S.15: Scientific or clinical representations • Ss.15(1) - this section does not apply to labels, CMIs or PILs • This section is in two parts: –Requirements for use of scientific or clinical claims (ss.15(2)) –Requirements for use of citations (ss.15(3)) 66
  • 68. S.15(2): Scientific or clinical claims Where an advertisement makes a scientific or clinical claim: • (a) any scientific or clinical terminology must be appropriate, clearly communicated and able to be readily understood by the audience to whom it is directed; and • (b) any scientific or clinical representation must be consistent with the body of scientific or clinical evidence applicable to the advertised therapeutic goods. 67
  • 69. S.15(3): Scientific citations Where an advertisement contains a citation to scientific or clinical literature, either explicitly or impliedly: • (a) any research results must identify the researcher and financial sponsor of the research, where the advertiser knows, or ought reasonably to have known that information; and • (b) the study must be sufficiently identified to enable consumers to access it. 68
  • 70. Example Implied scientific citation – reference needs to be provided Scientific information is inappropriate and won’t be readily understood These would need to reflect the body of evidence available 69
  • 71. Example Provided these claims reflect the body of evidence available about the product or ingredient, this would likely comply with s.15 70
  • 72. S.16(1): Endorsements • The endorsement provisions in section 16 do not apply to: –Testimonials captured by section 17 (s.16(1)(a)) –Claimer for efficacy assessed non-prescription medicines – as described in Regulations (s.16(1)(b)) 71
  • 73. S.16(2) and (2A): Endorsements • Endorsements (express or implied) from the following are prohibited: (a) a government authority, hospital or healthcare facility; or (b) an employee or contractor of a government agency, hospital or healthcare facility; or (c) a health practitioner, health professional, medical researcher or a group of such persons. • Health care facilities do not include community pharmacies 72
  • 74. S.16(3): Endorsements Subject to conditions, endorsements from the following are permitted: (a) an organisation that: (i) represents the interests of healthcare consumers; or (ii) represents the interests of health practitioners, health professionals or medical researchers; or (iii) conducts or funds research into any disease, condition, ailment or defect; or (b) an employee or contractor of an organisation mentioned above, other than an individual mentioned in paragraph (2)(b) or (c) 73
  • 75. S.16: Endorsement conditions • Endorsements made under s.16(3) are subject to the conditions that the advertisement: – names the organisation concerned; and – discloses: (i) the nature of the endorsement; and (ii) whether the organisation or employee, has received, or will receive, any valuable consideration for the endorsement • ‘Organisation’ defined in s.16(4) – any group, association etc 74
  • 76. S.17: Testimonials • Testimonial = a statement about a therapeutic good made by a person that claims to have used that good (s.17(1)) • This section specifies three types of requirements: – Characteristics of the person making testimonial (s.17(2)(a)) – Obligations of the advertiser before using testimonial in advertising (s.17(2)(b) and (c)) – Information that must be disclosed in the ad about the testimonial (s.17(3)) 75
  • 77. Who can make a testimonial for use in ads? s.17(2)(a) - a person: (i) whose details are verified prior to the advertising occurring; and (ii) who has used the goods for their intended purpose; and (iii) who is not: (A) involved with the production, sale, supply or marketing of the goods; or (B) an employee or officer of a corporation that is involved with the production, sale, supply or marketing of the goods; or (C) a corporation; or (D) mentioned in subsection 16(2) (e.g. health professionals, staff from government agency, hospital or healthcare facility) 76
  • 78. Advertiser obligations when using testimonials s.17(2)(b) and (c) – the advertiser needs to ensure that they have: • verified as to the use of the goods and the claims made by the person prior to the advertising occurring; and • checked that the testimonial is typical of the results to be expected from the use of the goods in accordance with the directions for use, or purpose, of the goods. 77
  • 79. Information re testimonials to be included in ads s.17(3) – An ad containing a testimonial must: (a) disclose whether the person providing the testimonial has received, or will receive, any valuable consideration for the testimonial; (b) disclose where another person is taking the place in the advertisement of the person providing the testimonial; and (c) disclose where the person providing the testimonial is an immediate family member of an individual who is involved with the production, sale, supply or marketing of the goods. 78
  • 80. Example acceptable use policy • We welcome your comments on our page but we ask that you help us comply with the Therapeutic Goods Advertising Code (the Code).Please consider these guidelines before commenting. We will remove any comments that may result in us breaching the Code. • We love when you comment and tag your friends and family on our posts but we ask that you do not: • endorse our product if you are: – an employee or contractor of a government authority, a hospital or a healthcare facility – a health practitioner, health professional or medical researcher – involved with the production, sale, supply or marketing of our product – not using your own name on this social media platform. • imply that a government authority, a hospital or a healthcare facility endorse our product • make comments about how a product works for you outside of its intended purpose, as these comments can be dangerous or misleading.—our products are developed for particular purposes, as stated on the label and/or in our advertising, and these comments can be dangerous and misleading – make comments about serious conditions, diseases, ailments or defects, such as comments about how a product helped with your cancer treatment or how it will relieve a tagged person’s rheumatoid arthritis pain • We also have an obligation to make sure any advertisements we make, including endorsements and testimonials, are not misleading. Therefore we promise to disclose: • where a person has been, or will be, compensated for making a testimonial • where we have actors making the testimonial, such as in cases where the original person who made the testimonial does not want to appear in our advertisement • where the person making the testimonial is an immediate family member of anyone employed by our business 79
  • 81. S.18: Incentives • Ads must not offer any personal incentive to a pharmacy assistant, or any retail sales person who is not a health professional, to recommend or supply therapeutic goods. • Pharmacy assistants and other retail staff do not meet the criteria for ‘health professionals’ for the purposes of the advertising (s.42AA) • Ads for these audiences must comply with the Code – including this provision 80
  • 82. S.19: Advertising to children • Advertising must not be primarily directed to children under the age of 12 years at all • Advertising must not be primarily directed to children aged 12 years or over, EXCEPT for those products listed in Schedule 2 of the Code, which include tampons and condoms • Labels are excluded from this provision • ‘primarily directed’ does not include incidental exposure 81
  • 83. S.20: Samples • An ad must not contain an offer of a sample EXCEPT for those products listed in Schedule 3: condoms Sunscreens Stoma devices for self-management Continence catheter devices for self-management • Samples can in themselves be an ad – consider Act definition of ‘advertise’ • Some samples may also be subject to state and territory laws – e.g. scheduled substances 82
  • 84. S.20: Samples example NOT COMPLIANT Have you been diagnosed with IBS recently? Wondering if you will ever find anything to help your symptoms? You can feel better in just two weeks – take the Bean’s challenge! Sign up at www.beanstonic.com.au and we will email you a voucher for a free one month supply of Bean’s Tonic from your local pharmacy 83
  • 85. S.21: Consistency with public health campaigns • If a relevant public health campaign of which the advertiser knows, or ought reasonably to have known is or will be current at the time of advertising therapeutic goods, the advertising must not be inconsistent with the public health campaign • Campaigns can be current but not necessarily active – e.g. respiratory hygiene campaigns only run in cold & flu season • Guidance contains more information on establishing current public health campaigns 84
  • 86. S.21: Consistency with public health campaigns Example: There are a range of current initiatives in Australia to encourage responsible alcohol consumption NOT COMPLIANT Drinkers Delight liver tonic • improves liver function • protects the liver from damage from alcohol consumption – especially on a big night out! Cheers! 85
  • 87. S.21: Consistency with public health campaigns Example: National tobacco campaign – an ongoing campaign to promote the quit smoking message across the national population NOT COMPLIANT SmokeProtect Natural antioxidants to protect the lungs from toxins in cigarette smoke Just one daily dose provides all the protection you need 86
  • 88. Part 3 - Requirements when advertising particular types of therapeutic goods 87
  • 89. S.22 - Application • Part 3 of the Code does not apply to: – Labels (as defined in s.3 of the Act) – Consumer medicine information leaflets (patient information documents as defined in Regs) – Patient information leaflets (implantable medical devices – see s.4 - Definitions) • These documents can still be considered promotional and have to comply with all other relevant Code provisions 88
  • 90. S.23 – Complementary medicines If an advertisement for a complementary medicine includes a claim or group of claims based on evidence of a history of traditional use, the reliance on this traditional use and paradigm must be disclosed in the advertisement and the disclosure must be prominently displayed or communicated in the advertisement. • This provision provides clarity around expectations for medicines advertised on the basis of traditional use 89
  • 91. S.23 – Complementary medicines • Some medicines rely on multiple paradigms – if this is the case, they need to be included in the ad. • Example:  Traditionally used in Ayurvedic medicine to relieve sleeplessness. Traditionally used in western herbal medicine to soothe restlessness.  Ingredient X is traditionally used in Ayurvedic and western herbal medicine to soothe sleeplessness and restlessness. 90
  • 92. S.24 – Analgesics • Oral analgesic ads must prominently display or communicate: INCORRECT USE COULD BE HARMFUL • The ad must not imply that analgesic consumption is safe or they can relax, relieve tension, sedate or stimulate • Definition of analgesic in s.4 – excludes combinations of analgesic and other ingredients for self limiting conditions • Needs to be used in conjunction with other mandatories • For radio ads 15s or less - FOLLOW THE DIRECTIONS FOR USE. INCORRECT USE COULD BE HARMFUL. 91
  • 93. S.25 – Vitamins and minerals An advertisement for vitamin or mineral supplements must not claim or imply that the supplements: • (a) are a substitute for good nutrition or a balanced diet; or • (b) are in any way superior to or more beneficial than dietary nutrients. 92
  • 94. S.26 – Goods for weight management (1) An advertisement for therapeutic goods containing any claim relating to weight management must balance the claims with the need for a healthy energy-controlled diet and physical activity. (2) Advertising of therapeutic goods containing any claim relating to weight management must not include any reference or depiction suggesting that the therapeutic goods will correct or reverse the effects of overeating or over-consumption of any food or drink. 93
  • 95. S.26 – Weight management (3) An advertisement for therapeutic goods containing any claim relating to weight management must not: (a) feature individuals in images or visual representations; or (b) use individuals’ statistics or testimonials; unless the results achieved by those individuals from the use of the goods would be expected to be achieved on average by users of the goods. 94
  • 96. S.27 – Sunscreens For an ad for a therapeutic good that is or contains a sunscreen that is claimed to prevent sunburn or skin cancer, the ad must: • depict sunscreens as being only one part of sun protection; and • include statements or visual representations, prominently displayed or communicated, to the effect that: – prolonged high-risk sun exposure should be avoided; and – frequent re-application or use in accordance with directions is required for effective sun protection. 95
  • 97. Part 4 – Restricted and prohibited representations 96
  • 98. Prohibited and Restricted Representations • The Act makes it a criminal offence, and provides civil penalties, where an advertiser makes reference certain conditions (explicitly, or by implication) in advertising of therapeutic goods without prior approval: – S. 42DL(7) and 42DLB(4) – restricted representations – S. 42DL(5) and 42DLB(2) – prohibited representations • The Act also provides that the Secretary may approve the use of these representations under certain circumstances (s.42DF and s.42DK) 97
  • 99. s.29(1)(a) – medically accepted to be a form requiring diagnosis, treatment or supervision by a suitably qualified health professional? s.29(1)(a) - Once medically diagnosed, is it medically accepted to be suitable for self-treatment and management? s.29(1)(b) - Is there a diagnostic/screening, or other kind of test for the form which requires medical interpretation or follow-up? The form IS a serious form NOT a serious form NO YES YES NO NO YES 98
  • 100. Restricted representations • A range of examples of what are and are not considered serious conditions are provided in the Guidance. • The conditions included in the Guidance make for a fairly easy assessment of whether or not they need to be medically diagnosed. • Where the serious condition is implied by the representation, this may be more difficult to assess 99
  • 101. Group discussion: Which conditions are prohibited or restricted representations? 100
  • 102. Permitted restricted representations • TGA has permitted the use of certain restricted representations by all advertisers of therapeutic goods, where the ad and product meets the characteristics and requirements specified. • Permitted restricted representations include: – Neural tube defect risk reduction in pregnancy when advertising medicines with at least 400µg folic acid/day – representations about sleep apnoea, Obstructive Sleep Apnoea (OSA) and Central Sleep Apnea/Apnoea (CSA) in relation to Continuous Positive Airway Pressure (CPAP) equipment 101
  • 104. S.30 - Prohibited representations • Representations (express or implied) about the treatment, cure, prevention, diagnosis (including screening), monitoring or susceptibility of, or pre- disposition to: – Neoplastic diseases (i.e. all types of cancer) – Sexually transmitted disease – HIV/AIDS – Hepatitis C virus – Mental illness • Abortifacient action 103
  • 105. Using prohibited representations • The use of a prohibited representation may be authorised where it is necessary for either: – Public health interest; or – The appropriate use of the goods (packaging & labelling only) • There is no process for applying to use prohibited representations – TGA will identify where it is needed • Representations about preventing transmission of STDs/HIV/AIDS and prevention of skin cancer through sunscreen use are prohibited representations but will be permitted 104
  • 106. Summary & finding more information 105
  • 107. Top tips for compliant 2019 advertising  Ensure ads contain the correct mandatory statements and information with appropriate prominence  Check advertising for complementary medicines, analgesics, vitamins, weight loss products and sunscreens carefully to ensure full compliance with the express provisions  Don’t use advertising with references to diseases, conditions, ailments or defects before checking if you need restricted representation approval 106
  • 108. Top tips for compliant 2019 advertising  Ensure testimonials, endorsements and scientific representations fully comply with clarified requirements  Don’t use advertising that is inconsistent with the product’s ARTG entry, directions, or instructions for use  Don’t use advertising that encourages people to delay seeking medical advice or cease prescribed therapies  Don’t use advertising that conflicts with public health campaigns 107
  • 109. More information on the 2018 Code • The 2018 Code: – Search “Advertising Code” on the TGA website • The 2018 Code guidance – Available from the Advertising Code page on the TGA website • The 2018 Code explanatory statement – Open the 2018 Code and click on ‘Explanatory statement’ button • More face to face and webinar education activities planned • Online training module planned 108
  • 110. More general advertising information • Advertising hub – www.tga.gov.au/advertising-hub – Online training module – more to come – Australian Regulatory Guidelines for Advertising Therapeutic Goods • Regulatory affairs consultant / legal advice • TGA Online advertising inquiry form - https://compliance.tga.gov.au/advertising-enquiry/ 109
  • 111. TGA website www.tga.gov.au TGA Advertising Hub https://www.tga.gov.au/advertising-hub • Facebook https://www.facebook.com/TGAgovau/ Twitter https://twitter.com/TGAgovau youtube https://www.youtube.com/channel/UCem9INJbMSOeW1Ry9cNbucw More on TGA visit…………….. 110
  • 112. Questions on the 2018 Code? 111
  • 113. 112

Editor's Notes

  1. Introduce speakers Housekeeping – scheduled break, toilets, amenities No photos or recording
  2. Before we get into the details, I’d like to provide some context about the Code, in particular the 2018 Code, and this session Firstly, it’s useful to remind ourselves of the overarching requirements relating to the advertising of therapeutic goods, including the legislative basis for compliance with the code. As we identified in the earlier session on the legislative overview, there are a range of advertising requirements specified in the Act that have to be met. This includes the requirement to comply with the Code.
  3. The 2018 Code applies from 1 January 2019, but was made available from 1 July 2018 to allow advertisers to familiarise themselves with the new requirements Prior to the 2018 Code, the Code had not been substantially changed since 2007. It no longer reflected contemporary legislative drafting styles, language or best practice. Very principles based, which makes it difficult to enforce. Code needed to be amended to clarify requirements and create more objective tests to be able to support enhanced sanctions and penalties made available with the Act changes in March 2018 (like directions and infringement notices). Following a series of public consultations, the 2018 Code was made on 29 June 2018. In the intervening period, we have continued to engage with our stakeholders, who have identified a range of concerns, including areas of ambiguity. As a result a number of opportunities to improve the 2018 Code have been identified to provide advertisers with the clarity they need to apply the code correctly. These improvements are expected to be made to the Code and published this week. The improvements include a number of administrative changes (e.g. referring to the Code as an ‘instrument’). This presentation is based on the revised 2018 Code as we expect it to be made and we have made our best efforts to ensure it reflects the current position. However, I’m sure you will appreciate that until the delegate of the Minister formally signs the Code, it’s not set in stone. When the final Code guidance is released, it will reflect the revisions to the 2018 Code. We don't anticipate that the proposed improvements will cause inconvenience to advertisers who have already prepared advertising based on the 2018 Code as made on 29 June 2018. Such advertisers are likely to exceed the minimum requirements rather than be non-compliant. You should check the TGA website in the next few days for the amended Code and guidance. Throughout the presentation, I have highlighted departures from the 2018 Code as made in purple text. However, from now on, any references to the 2018 Code, you should take to mean a reference to the 2018 Code as we expect it to be amended Your folders include a copy of the 2018 Code as made for reference.
  4. The version of the Code applied to applications for pre-approval will depend on when the application is to be decided.
  5. We have been asked how we propose to carry out investigations into alleged non-compliance with the 2018 Code in the period from 1 January 2019 to 30 June 2019. We will cover this off in the complaints handling session later on.
  6. We understand that advertisers are working hard to update systems and processes for the new Code and that, particularly for larger companies, advertisements go through a strong governance process for approval. Stakeholders have asked us about the compliance actions the TGA may take in relation to advertising that complies with the 2015 Code but not the 2018 Code, particularly around the prominent display of mandatory information (such as health warnings), where the advertising remains in place after 1 January 2019 (including in stores) while advertisers are transitioning their advertisements. We will take a pragmatic approach to our compliance activity during 2019 while following our complaints management process outlined in Complaints handling for the advertising of therapeutic goods. When categorising advertising complaints we take into account a number of factors, including the risk posed to public health and safety. Where an advertiser publishes an ad that is not compliant with the 2018 Code, but would have been compliant with the 2015 Code, in particular in relation to requirements such as the mandatory statement used, scientific citations and testimonial disclosures, this is unlikely to pose a significant risk to public health. In the event that a complaint is received during the first half of 2019 alleging non compliance of this type, the action taken will involve a reminder about the advertising obligations under the 2018 Code, but is unlikely (in the absence of other non-compliance) to attract more serious action. In the second half of 2019, where a complaint is received or a matter of non-compliance identified, we will seek information such as the process being applied to correct the advertising along with associated dates (including the date corrective action commenced) before determining whether to apply enforcement discretion. For specified advertising that has been pre-approved under the Therapeutic Goods Regulations 1990 on the basis of the 2015 Code, any complaints will be considered against the 2015 Code. For more information, see the changeover period.
  7. Structurally, the 2018 Code is rather different to the 2015 Code. This is an overview and we will examine the provision in further detail using examples. Part One – usual preliminary material found in legislation/legislative instruments Part 2 – sets out the requirements that apply to all advertising of therapeutic goods to consumers Part 3 – Drills down into specific products – complementary medicines, vitamins and minerals, weight management, analgesics and sunscreens Part 4 – This part covers what you can’t say - there are certain serious conditions that are not permitted in advertising without express approval Schedule 1 – Warning statements – such as do not use if pregnant Schedule 2 – Children Schedule 3 – Samples Schedule 4 – Price information Schedule 5 – Repeals the 2015 Code and the version of the 2018 Code that was made in July, meaning that version will never take practical effect
  8. Other definitions we will look at as we encounter them through the actual Code provisions. We know that these two have been of considerable concern to advertisers and so we will explore them fully and with examples.
  9. Health warnings are required to be included in advertisements where consumers have vulnerabilities, associated with certain conditions or where there are possible adverse outcomes from the use of the therapeutic good where used as directed. The purpose is to ensure that a consumer has e relevant health and safety information available to them when self selecting a therapeutic good, or doing so in consultation with their pharmacist. S4 provides a definition for health warnings, directing us to Schedule One for medicines and providing a further definition for devices. This definition was arrived at on the basis that warnings meeting this definition are information that consumers need to know before seeking out and purchasing the advertised goods.
  10. Inclusion criteria – contraindications Schedule one is an exhaustive list, but will be updated from time to time. It incorporates the Required Advisory Statements for Medicine Labels, and TGO 69 and 92 Labeling orders. These are short form health warnings, designed to be accessible to consumers and to make comprehension easy.
  11. Mention that requirement to identify new allergens added in TGO92 won’t commence until compliance with TGO92 is mandatory (1 Sep 2020), unless the sponsor has chosen to comply with TGO92 instead of TGO69 before this date. Does your product contain an ingredient from column one? In the circumstances identified in Column 2? Then include the warning in column 3! Questions at ASMI seminar – In the new Schedule 1 for medicines, what’s included – active and/or non-active ingredients? We are we disclosing excipient warnings (like gluten etc) in health warnings?
  12. The 2018 Code allows for the use of the statement 'THIS PRODUCT MAY NOT BE RIGHT FOR YOU. READ THE LABEL BEFORE PURCHASE' as an alternative to the inclusion of the applicable health warnings.
  13. Health warnings, plus other important information are required under the 2018 Code to be ‘prominently displayed or communicated’. This is not a new concept – the need to ‘prominently display or communicate important information in advertising features in the 2015 Code too. However, we have clarified the definition and we are producing specific examples to demonstrate how the definition is interpreted and applied. Guidance and education, including the examples we will hand out today, will include clear examples of statements that meet or exceed the requirement to be 'prominently displayed or communicated'. We will look at some examples later. As with many aspects of advertising, what is reasonable is informed by context. EXAMPLE: Riding motorbike on highway - ourdoor advertising? What font size would be easily read and understood? Muttering and speaking really fast may not be considered clearly heard and understood With TVC it is preferable that both elements fulfil the requirements. Questions at ASMI seminar – What’s a “reasonable viewing distance”? For outdoor advertising we are being asked for exact dimensions and distance away from the viewer, including those in a moving car. We need recommendations/guidance on this. In a TVC with both visual and spoken do both elements need to fulfil the requirements?
  14. Principles underpin how we regulate the advertising of therapeutic goods to Australian consumers. Imports the concept of Quality Use of Medicines and reflects those principles in application to all therapeutic goods. Ultimately supports consumer safety and favorable public health outcomes. There is a very strong consumer focus, making sure that advertisers to not behave in a way that misleads or deceives the consumer or makes claims about a product that are unfounded.
  15. EG – Medical breakthrough on the news, or a positive surgical outcome
  16. What is the takeaway message for the consumers? Think about your target audience and their particular vulnerability. It is about the impact on the person who would be purchasing your goods, based on the claims you are making. You may be marketing to the world at large, or to a particular sub population. That sub-population may have specific vulnerabilities. What does your ad in totality demonstrate? Do not consider the words and images separately – your words may be compliant but the accompanying image may denote a miraculous outcome.
  17. NUANCE IT DEPENDS CONTEXT
  18. What are the audiences for each of these ads? What is the reasonable consumer likely to be like in each case? Think about the population subset Characteristics Vulnerabilities
  19. Example showing how presentation & context important and how reasonable consumer assessed So on the left, we have an editorial article about IBS and then an ad for an IBS product on the right. How is a consumer likely to interpret the ad after reading the article? What sort of reasonable consumer is this ad directed to?
  20. Won’t talk about price information any further today – if you have questions, see me in the break
  21. Number does not have to be prominently displayed
  22. A ‘valid’ claim is one that is authoritative, sound or well-founded, while an ‘accurate’ claim conforms to the truth and is free from error (relying on the ordinary meaning of these words in the Macquarie Dictionary).An accurate claim is a truthful claim and is correct. 
  23. Questions at ASMI seminar – What’s the definition of consistent when it comes to wording between the ARTG and advertising (example given: some ASMs are asking that the wording be absolutely identical)? In relation to permitted indications what’s the advice in relation ‘can/may’? ASMs need guidance.
  24. Also note the IBS example we discussed earlier with the editorial one side and ad on the other – combination of two would result in delaying appropriate treatment
  25. Therapeutic goods exert a therapeutic effect on the human body. Therefore, the good may also have unintended consequences or trigger an adverse event. For these reasons, this section of the Code specifically prohibits the advertising of a therapeutic good as safe or having no side-effects, even for specific patient populations or particular dosages. This requirement applies even if you think you have evidence to substantiate such a claim.
  26. Example * implying that the consumer’s health may suffer by not using the advertised good * implying that the use of an advertised good is essential for normal health 
  27. This table shows the interactions between sections 11, 12, 13 at a high level. There are of course different requirements within sections 11, 12 and 13 but this shows which section(s) apply to which types of ads – we will go through these in detail now
  28. Irrespective of whether section 12 or 13 applies to your ad, there are some fundamental pieces of information that must be included.
  29. Remember these are just the minimum requirements – advertisers may choose to provide more information than specified in this section.
  30. In addition, the ad must include any additional statements required by Part 3 of the Code as appropriate to the type of product Questions at ASMI seminar: What order do the mandatories have to appear in? Does “this medicine may not be right for you” have to come first? s.12 medicines with a health warning – where do the health warnings sit in internet advertising – on the banner ad or page that introduces the product; or on the ‘buy now’ page; or both? Is there any flexibility in the way the mandatories are written –‘or words to that effect’?
  31. In addition, the ad must include any additional statements required by Part 3 of the Code as appropriate to the type of product
  32. In addition, the ad must include any additional statements required by Part 3 of the Code as appropriate to the type of product
  33. In addition, the ad must include any additional statements required by Part 3 of the Code as appropriate to the type of product Question at ASMI seminar- What’s the expectation in relation repetition (prominently displayed) for ads on the internet where things move? How often do the mandatories need to be repeated? What about in a 30sec TVC, or websites that you scroll through?
  34. In addition, the ad must include any additional statements required by Part 3 of the Code as appropriate to the type of product
  35. In addition, the ad must include any additional statements required by Part 3 of the Code as appropriate to the type of product
  36. Question from ASMI session - How does the requirement for mandatory statements plus prominently displayed work for twitter, Instagram, something less than 300 words, or search outputs? You need a framework for digital – people might see the 300 words as a ‘get out of jail free’ card and stay under this limit to avoid the mandatories.
  37. Subsection 15(3) of the 2018 Code will be amended to clarify the information that needs to be included in advertising that contains a citation to scientific literature. The 2018 Code guidance will also be updated to explain what is meant by the reference in this section to 'implied' citations. For example, a reference to 'claims being clinically proven' implicitly makes a citation to scientific literature; in this case, the research results must identify the researcher and the financial sponsor. A statement of the duration of the therapeutic use of the good, for example, that it works for up to 8 hours, makes no citation because there is no explicit or implicit mention of the existence of scientific literature in support of the claim. In this case, no obligation arises under section 15. For clarity, we are making references consistent within the section to demonstrate it covers both scientific and clinical representations
  38. Questions from ASMI session – s.15 what happens if journal articles can only accessed by subscription, should they be referenced? What if the name of the article/journal includes a restricted representation? (took on notice) If an advertisement doesn’t say ‘clinically proven’ then does s.15 apply? What do you do if you are relying on an unpublished study, or something that is commercial-in-confidence? What about an R&D study done by the company actually developing the product, can you cite this?
  39. But what won’t it comply with?
  40. The claimer was the subject of a consultation in May-June 2018. When a decision is made in relation to the claimer, the Code will specifically exempt the claimer from the operation of the s.16 provisions. A similar arrangement has been made for the s.42DL(9)(c) prohibition in the Act. Question from ASMI session: s.16(1) If something is developed in house in a hospital by a particular doctor, is this an endorsement?
  41. A new subsection (ss.16(2A)) is proposed to clarify that health care facilities do not include a community pharmacy Question from ASMI session - s.16(2) how does claiming something is scientifically formulated now work?
  42. (2)(b) and (C): (b) an employee or contractor of a government agency, hospital or healthcare facility; or (c) a health practitioner, health professional, medical researcher or a group of such persons. Question from ASMI session - What if a hospital helps develop a specific formulation, what wording would we use (s.16(3))? (took on notice)
  43. For the purposes of subsection (3), an organisation means any group, association or body (whether incorporated or unincorporated), of a kind mentioned in paragraph (3)(a ).   Proposed change, principally to clarify that an organisation for the purposes of the above that represents consumers, health practitioners, health professionals or researchers, may be either incorporated or unincorporated.
  44. Person may have used the goods themselves or on someone they are related to e.g. a child or parent Where the person used the product on someone else in a commercial context (e.g. service delivery), it would be an endorsement Hand out testimonials examples and discuss if there is time Questions from ASMI session – How do we express a testimonial on Instagram or in a blog? What if the testimonial if fine except for one word – what do we do? What’s the tipping point between a paid testimonial and that person actually marketing a product (like a brand ambassador)? (took on notice)
  45. (iii)(C) just a minor wording change for consistency
  46. An ad does not need to disclose where an actor is being paid to take the place of the testifier in the ad – only if valuable consideration was given to the person providing the testimonials s.17(3)(a) is likely to be amended for consistency with s.16(3)(d)(ii) – endorsements – required to disclose whether any valuable consideration has been or will be provided. We received feedback that in relation to s.17(3)(c), “a relative or associate” was too ambiguous and potentially too broad. As such, we are likely to constrain it to “immediate family member”.
  47. If the content is non-promotional (e.g. educational), the Code will not apply. However, the inclusion of an offer of a personal incentive to recommend or supply particular goods is likely to result in the content being considered an advertising.
  48. This provision has changed somewhat from the 2015 Code. Under the 2015 Code, any of the items listed (including tampons and condoms) could be advertised to children under 18. However, children are a particularly vulnerable population group in terms of advertising. Many children are unlikely to have developed sufficient knowledge or reason to make responsible choices in relation to therapeutic goods or to understand the generally persuasive intent of advertising. Choices about when and how therapeutic goods may be appropriate for them are rightly made by the adult who looks after the interests of the child. It would therefore not be ethical or socially responsible to target children in advertisements for therapeutic goods. There are exceptions in relation to specific therapeutic goods for children 12 years and over, consistent with their increasing independence from adults. These requirements do not apply to labels, on which characters, colouring, fonts and other artefacts may be used to identify therapeutic goods for use in children, including to differentiate children’s dosage forms from adult preparations. The concept of ‘primarily directed’ to a particular audience does not capture incidental exposure by these audiences. For example, if an 11 year old was incidentally exposed to a tampon ad by looking over her 14 year old sister’s shoulder while looking at Dolly magazine online, this would not be considered a breach of this provision. But if the ad appeared on the Nickelodeon website, which specifically targets younger children, it would be a different story. We have also received some questions about a potential conflict between this provision and the fact that many pharmacy assistants and other sales staff are under 18. However, where such materials were directed to such staff in general – as opposed to being primarily directed to the younger staff – it would be unlikely to contravene this provision. Also, if educational, the Code (including this provision) won’t apply at all
  49. We are also likely to add lubricants (other than eye lubricants) that do not contain a local anaesthetic, stoma and continence catheter products for self management to the list of sample exemptions. Have the definition of advertise from the Act available for point 2 The stoma and catheter entries were added in acknowledgement of a government program under which nurses make recommendations to stoma patients about which products approved under the stoma appliance scheme may be suitable for them and people are given samples to use to see if it is right for them If there is a good public health reason to do so, we may add more items down the track
  50. The object of the 2015 Code is to ensure that the marketing and advertising of therapeutic goods to consumers is conducted in a manner that promotes the quality use of therapeutic goods and is socially responsible. In order to be consistent – or at least not at odds - with these objectives, advertising for therapeutic goods must not be inconsistent with public health campaigns. As such, there is now an express requirement in the 2018 Code to this effect. Change (in purple) proposed to reflect feedback from stakeholders during recent consultation period. Public health messages are an investment by the Government to improve public health and safety and are based on considerable research and expert advice. The objective of this provision is to ensure that that advertising of therapeutic goods does not undermine or otherwise diminish the message contained in government public health campaigns. Sections 5 and 21 of the 2018 Code will be amended to clarify that only those public health campaigns of which the advertiser could reasonably be expected to be aware will be relevant to compliance with these provisions. This reflects our expectation in practice that advertisers should not need to be aware of isolated public health campaigns (e.g. conducted by an individual local council) to ensure compliance with this aspect of the 2018 Code.
  51. Referring to indications that are supported by evidence of traditional use inappropriately in advertising for complementary medicines has the potential to mislead consumers about the type of supporting evidence for the medicine. For this reason, where the advertiser is relying on traditional evidence to support an indication referenced in an advertisement, the advertiser must clearly disclose to the viewer that this is the case and identify the paradigm of the traditional use. This information must be clearly disclosed in the advertisement. Paradigms include, but are not limited to: traditional Chinese medicine Ayurvedic medicine western herbal medicine homoeopathy To be considered to be prominently displayed or communicated, this information would need to be portrayed as part of, or in very close proximity to, the therapeutic claims. Question from ASMI session - s.23 what about products developed for a particular group/category – do you have to cross reference to other categories (like traditional medicine)?
  52. Under the 2015 Code, the analgesics requirements were generally well understood and applied. In 8 years, the CRP only upheld a handful of complaints in relation to those requirements. But it’s still an important requirement to have – the misuse and overuse of oral analgesics in Australia is still a public health concern so it’s appropriate that advertising for such goods reflect appropriate use and not inadvertently encourage inappropriate use. The 2018 code has retained the principles from the 2015 Code. The definition of ‘analgesic’ has been moved to the Definitions section: analgesic means a medicine for internal use (i.e. oral), containing one or more of the following substances intended for the relief of aches and pains:                      (a)  salicylic acid, its salts, its derivatives (including aspirin) and their salts;                      (b)  other non-steroidal anti-inflammatory drugs;                      (c)  paracetamol; not including such a medicine where:                      (d)  the condition for which it is designed is a self-limiting condition; and                      (e)  the substances mentioned in paragraphs (a)-(c) are combined with one or more other active ingredients; and                       (f)  the other ingredients have been included in the medicine for indications other than the relief of aches and pains. Note the requirement to prominently display or communicate this warning. It will also need to be displayed in conjunction with other warnings prescribed under sections 11, 12, 13 and 14 as applicable. The 2015 Code effectively exempted radio ads 15 seconds or less from including this statement (they only had to state Always read the label.  Use only as directed by a healthcare professional). This exemption no longer applies. However, such ads will be exempt from the requirement to state Always read the label (s.11(5)) and “If symptoms persist…”. Reflects that many analgesics are now available outside pharmacy. Question from ASMI session - s.24 does this need to be next to the product or could it be in the terms and conditions at the bottom of an advertisement?
  53. This requirement is largely unchanged from the 2015 Code and is pretty straight forward.
  54. Proposed change to clarify the intention is that this applies to both primary and secondary sunscreens Australia has one of the highest rates of skin cancer in the world. Melanoma is the third most common cancer (Melanoma Institute Australia – website accessed 13/10/18). The s.26BF permissible indications and s.26BB permitted ingredients determinations require sunscreens to carry a label statement to the effect that “Prolonged exposure to the sun should be avoided, it is important to wear protective clothing, hats and eyewear when exposed to the sun.”. Labelling also needs to include information about reapplying regularly. In order for advertising of sunscreens to be socially responsible, it needs to reflect these conditions of use.
  55. PROHIBITED REPRESENTATIONS – DO NOT USE UNLESS SUBJECT TO AN EXISTING APPROVAL BY THE DEPARTMENT OF HEALTH RESTRICTED REPRESENTATIONS – YOU MUST APPLY TO USE AND YOUR APPLICATION MUST BE APPROVED PRIOR TO YOU USING THEM PUT YOURSELF IN THE SHOES OF THE CONSUMER WITH THAT CONDITIONS CONSIDDER THEIR VULNERABILITIES CONSIDER THE PUBLIC INTEREST CONSIDER THE IMPACT YOUR ADVERTISING MAY HAVE IF IN DOUBT, ASK A REG AFFAIRS CONSULTATANT, YOUR REGULATION TEAM, CONSULT THE GUIDANCE, OR CONTACT US
  56. WHY? Why do we care about the use of these representations? We know therapeutic goods are not ordinary consumer goods, that is why they are subject to further regulation. Restricted and prohibited representations require scrutiny because of the enhanced vulnerabilities of particular consumers. The use of these representations requires detailed consideration by the TGA to ensure such use does not compromise individual or public health and to ensure that the representations are accurate, balanced and not misleading. We will start by considering restricted representations, as you may find you have a product you want to advertise that includes representations that require approval WHAT IS A RESTRICTED REPRESENTATION? It is a serious form of a disease, condition, ailment or defect. How do we know if it is a serious form?
  57. The guidance includes a ready reckoner – table to assist with some common conditions WHERE THE SERIOUS CONDITION IS IMPLIED BY THE REPRESENTATION IT IS MORE DIFFICULT TO ASSESS: SUCH AS OUR DIABETES EXAMPLE
  58. REFER TO EARLIER SLIDE
  59. Question at ASMI seminar - What happens if you have a restricted representation, are these included in the health warnings?
  60. WE DO APPROVE THE USE OF RESTRICTED REPRESENTATION, UNDER CERTAIN CIRCUMSTANCES: We will approve the use of a restricted representation where it is accurate, balanced and not misleading; and Where it meets the public interest criteria: Does not take advantage of the vulnerable consumer Be likely to result in the consumer not seeking timely advice Negative impact on public health
  61. Example to consider: Lactation support supplement– assists with mood, stress and mild anxiety
  62. The hub also contains Regulatory decisions and outcomes
  63. Prompt people to fill in evaluation form